<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Kymriah II-30 - EN PI clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:85.05pt;
	text-indent:-85.05pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Annotationtext\,Comment Text Char Char Char\,Comment Text Char1 Char\,Kommentartext";
	mso-style-link:"Comment Text Char\,Annotationtext Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char Char\,Kommentartext Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
span.MsoCommentReference
	{mso-style-name:"Comment Reference\,Kommentarzeichen";}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Annotationtext Char\,Comment Text Char Char Char Char\,Comment Text Char1 Char Char\,Kommentartext Char";
	mso-style-link:"Comment Text\,Annotationtext\,Comment Text Char Char Char\,Comment Text Char1 Char\,Kommentartext";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Text, li.Text, div.Text
	{mso-style-name:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C\,Text_10394\,non tochic\,notic";
	mso-style-link:"Text Char\,Graphic Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listlevel2, li.Listlevel2, div.Listlevel2
	{mso-style-name:"List level 2";
	mso-style-link:"List level 2 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.5pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.TextChar
	{mso-style-name:"Text Char\,Graphic Char";
	mso-style-link:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C\,Text_10394\,non tochic\,notic";
	font-family:"MS Mincho";}
span.Listlevel2Char
	{mso-style-name:"List level 2 Char";
	mso-style-link:"List level 2";
	font-family:"MS Mincho";}
p.Comment, li.Comment, div.Comment
	{mso-style-name:Comment;
	mso-style-link:"Comment Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:#BF30B5;
	font-style:italic;}
span.CommentChar
	{mso-style-name:"Comment Char";
	mso-style-link:Comment;
	font-family:"MS Mincho";
	color:#BF30B5;
	font-style:italic;}
p.Table, li.Table, div.Table
	{mso-style-name:"Table\,\(Complex\) Arial\,10 pt\,10 pt  Bold\,9 pt\,9pt\,After\:  0 pt\,Before\:  0 pt\,Bold\,Courier New\,Normal + \(Latin\) Arial\,Normal + Courier New\,Not Bold\,Table + \(Latin\) Courier New\,Table pt\,Text + Courier New\,legendpt\,legendt\,table text 10 pt + Arial";
	mso-style-link:"Table Char\,\(Complex\) Arial Char\,10 pt  Bold Char\,10 pt Char\,9 Char\,9 pt Char\,9pt Char\,Be\.\.\. Char\,Bold Char\,Italic Char\,Justified Char\,Left\:  0\0022 Char\,Normal + \(Latin\) Arial Char\,Normal + Courier New Char\,Table pt Char\,table text 10 pt + Arial Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.Legend, li.Legend, div.Legend
	{mso-style-name:Legend;
	mso-style-link:"Legend Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.LegendChar
	{mso-style-name:"Legend Char";
	mso-style-link:Legend;
	font-family:"Arial",sans-serif;}
span.TableChar
	{mso-style-name:"Table Char\,\(Complex\) Arial Char\,10 pt  Bold Char\,10 pt Char\,9 Char\,9 pt Char\,9pt Char\,Be\.\.\. Char\,Bold Char\,Italic Char\,Justified Char\,Left\:  0\0022 Char\,Normal + \(Latin\) Arial Char\,Normal + Courier New Char\,Table pt Char\,table text 10 pt + Arial Char";
	mso-style-link:"Table\,\(Complex\) Arial\,10 pt\,10 pt  Bold\,9 pt\,9pt\,After\:  0 pt\,Before\:  0 pt\,Bold\,Courier New\,Normal + \(Latin\) Arial\,Normal + Courier New\,Not Bold\,Table + \(Latin\) Courier New\,Table pt\,Text + Courier New\,legendpt\,legendt\,table text 10 pt + Arial";
	font-family:"Arial",sans-serif;}
p.Listlevel1, li.Listlevel1, div.Listlevel1
	{mso-style-name:"List level 1";
	mso-style-link:"List level 1 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Nottoc-headings, li.Nottoc-headings, div.Nottoc-headings
	{mso-style-name:"Not toc-headings";
	mso-style-link:"Not toc-headings Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Nottoc-headingsChar
	{mso-style-name:"Not toc-headings Char";
	mso-style-link:"Not toc-headings";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Calibri",sans-serif;}
span.text-h1
	{mso-style-name:text-h1;
	font-family:"Times New Roman",serif;}
span.st1
	{mso-style-name:st1;}
span.Listlevel1Char
	{mso-style-name:"List level 1 Char";
	mso-style-link:"List level 1";
	font-family:"MS Mincho";}
p.JPSAStext, li.JPSAStext, div.JPSAStext
	{mso-style-name:"JP SAS text";
	margin:0in;
	font-size:9.0pt;
	font-family:"Courier New";
	letter-spacing:-.5pt;}
p.JPTable, li.JPTable, div.JPTable
	{mso-style-name:"JP Table";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.Docstatus, li.Docstatus, div.Docstatus
	{mso-style-name:Docstatus;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.a, li.a, div.a
	{mso-style-name:a;
	mso-style-link:"Merknadstekst Tegn\,Comment Text Char Char Char Tegn\,Comment Text Char1 Char Tegn";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.MerknadstekstTegn
	{mso-style-name:"Merknadstekst Tegn\,Comment Text Char Char Char Tegn\,Comment Text Char1 Char Tegn";
	mso-style-link:a;
	font-family:"Times New Roman",serif;}
p.a0, li.a0, div.a0
	{mso-style-name:a0;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a1, li.a1, div.a1
	{mso-style-name:a1;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a2, li.a2, div.a2
	{mso-style-name:a2;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a3, li.a3, div.a3
	{mso-style-name:a3;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a4, li.a4, div.a4
	{mso-style-name:a4;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a5, li.a5, div.a5
	{mso-style-name:a5;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a6, li.a6, div.a6
	{mso-style-name:a6;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a7, li.a7, div.a7
	{mso-style-name:a7;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.a8, li.a8, div.a8
	{mso-style-name:a8;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Merknadsreferanse1
	{mso-style-name:Merknadsreferanse1;}
span.MerknadstekstTegn1
	{mso-style-name:"Merknadstekst Tegn1\,Comment Text Char Char Char Tegn1\,Comment Text Char1 Char Tegn1";
	font-family:"Times New Roman",serif;}
p.a9, li.a9, div.a9
	{mso-style-name:a9;
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.MerknadstekstTegn2
	{mso-style-name:"Merknadstekst Tegn2\,Comment Text Char Char Char Tegn2\,Comment Text Char1 Char Tegn2";
	font-family:"Times New Roman",serif;}
p.aa, li.aa, div.aa
	{mso-style-name:aa;
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.normaltextrun1
	{mso-style-name:normaltextrun1;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img width=20
height=18 src="Kymriah%20II-30%20-%20EN%20PI%20clean_files/image001.gif"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicinal product is subject
to additional monitoring. This will allow quick identification of new safety
information. Healthcare professionals are asked to report any suspected adverse
reactions. See section&nbsp;4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.       NAME OF </span></b><b><span
lang=EN-GB>THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah 1.2&nbsp;x&nbsp;10<sup>6</sup>&nbsp;–&nbsp;6&nbsp;x&nbsp;10<sup>8</sup>
cells dispersion for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.       QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.1     General description</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah is an
immunocellular therapy containing tisagenlecleucel, autologous T cells
genetically modified <i>ex vivo</i> using a lentiviral vector encoding an anti&#8209;CD19
chimeric antigen receptor (CAR).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.2     Qualitative and
quantitative composition</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each </span><span
lang=EN-GB>ethylene vinyl acetate (EVA) infusion bag of Kymriah </span><span
lang=EN-GB>contains tisagenlecleucel cell dispersion at a batch&#8209;dependent
concentration of </span><span lang=EN-GB>autologous T cells genetically
modified to express an </span><span lang=EN-GB>anti&#8209;CD19 chimeric antigen
receptor</span><span lang=EN-GB> (CAR&#8209;positive viable T cells) (see section&nbsp;4.2)</span><span
lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The concentration of CAR&#8209;positive viable T cells is dependent
on indication and patient body weight (for B&#8209;cell acute lymphoblastic
leukaemia [ALL]). The cellular composition</span><span lang=EN-GB> </span><span
lang=EN-GB style='color:black'>and the final cell number varies between
individual patient batches. In addition to T cells, NK cells may be present. The
quantitative information regarding CAR&#8209;positive viable T cells/mL and
total cells in the product is presented in the batch&#8209;specific documentation
accompanying Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 or more infusion
bags containing a total of 1.2&nbsp;x&nbsp;10<sup>6</sup> to 6&nbsp;x&nbsp;10<sup>8</sup>
CAR&#8209;positive viable T cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
page-break-after:avoid;text-autospace:none'><u><span lang=EN-GB>Excipient with
known effect</span></u></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
page-break-after:avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>This medicinal product contains 2.43&nbsp;mg sodium per mL
and 24.3 to 121.5&nbsp;mg sodium per dose.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.       PHARMACEUTICAL </span></b><b><span
lang=EN-GB style='font-family:"Times New Roman Bold",serif'>FORM</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Dispersion for infusion.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A colourless to
slightly yellow dispersion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.       </span></b><b><span
lang=EN-GB>CLINICAL</span></b><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>
PARTICULARS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1     Therapeutic
indications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kymriah is indicated for the treatment of:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Paediatric and young adult patients up to and
including 25&nbsp;years of age with B&#8209;cell acute lymphoblastic leukaemia
(ALL) that is refractory, in relapse post&#8209;transplant or in second or
later relapse</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Adult patients with relapsed
</span><span lang=EN-GB>or refractory diffuse large B&#8209;cell lymphoma
(DLBCL) after two or more lines of systemic therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2     Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah must be
administered in a qualified treatment centre. Therapy should be initiated under
the direction of and supervised by a healthcare professional experienced in the
treatment of haematological malignancies and trained for administration and
management of patients treated with Kymriah. Tocilizumab for use in the event
of cytokine release syndrome and emergency equipment must be available per
patient prior to infusion. The treatment centre must have access to additional
doses of tocilizumab within 8&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah is
intended for autologous use only (see section&nbsp;4.4). Manufacture and
release of Kymriah usually takes about 3&#8209;4&nbsp;weeks.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Dosage in paediatric and young adult B&#8209;cell ALL patients</span></u></i></p>

<p class=Listlevel2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>For patients 50&nbsp;kg
and below: 0.2 to 5&nbsp;x&nbsp;10<sup>6</sup> CAR&#8209;positive viable T
cells/kg body weight.</span></p>

<p class=Listlevel2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>For patients above
50&nbsp;kg: 0.1 to 2.5&nbsp;x&nbsp;10<sup>8</sup> CAR&#8209;positive viable T
cells (non&#8209;weight based).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Dosage in adult DLBCL patients</span></u></i></p>

<p class=Listlevel2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>0.6 to 6&nbsp;x&nbsp;10<sup>8</sup>
CAR&#8209;positive viable T cells (non&#8209;weight based).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pre&#8209;treatment conditioning (lymphodepleting chemotherapy)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lymphodepleting
chemotherapy is recommended to be administered before Kymriah infusion unless
the white blood cell (WBC) count within one week prior to infusion is
&#8804;1,000&nbsp;cells/&#956;L.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah is
recommended to be infused 2 to 14&nbsp;days after completion of the
lymphodepleting chemotherapy. The availability of Kymriah must be confirmed
prior to starting the lymphodepleting regimen. If there is a delay of more than
4&nbsp;weeks between completing lymphodepleting chemotherapy and the infusion
and the WBC count is &gt;1,000&nbsp;cells/&#956;L, then the patient should be
re&#8209;treated with lymphodepleting chemotherapy prior to receiving Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><i><u><span lang=EN-GB style='font-size:11.0pt'>B&#8209;cell ALL</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>The recommended
lymphodepleting chemotherapy regimen is:</span></p>

<p class=Listlevel2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Fludarabine (30&nbsp;mg/m<sup>2</sup>
intravenous daily for 4&nbsp;days) and cyclophosphamide (500&nbsp;mg/m<sup>2</sup>
intravenous daily for 2&nbsp;days starting with the first dose of fludarabine).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If the patient experienced a previous Grade&nbsp;4 haemorrhagic
cystitis with cyclophosphamide, or demonstrated a chemorefractory state to a
cyclophosphamide&#8209;containing regimen administered shortly before
lymphodepleting chemotherapy, then the following should be used:</span></p>

<p class=Listlevel2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Cytarabine (500&nbsp;mg/m<sup>2</sup>
intravenous daily for 2&nbsp;days) and etoposide (150&nbsp;mg/m<sup>2</sup> intravenous
daily for 3&nbsp;days starting with the first dose of cytarabine).</span></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><i><u><span lang=EN-GB style='font-size:11.0pt'>DLBCL</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>The recommended
lymphodepleting chemotherapy regimen is:</span></p>

<p class=Listlevel2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Fludarabine (25&nbsp;mg/m<sup>2</sup>
intravenous daily for 3&nbsp;days) and cyclophosphamide (250&nbsp;mg/m<sup>2</sup>
intravenous daily for 3&nbsp;days starting with the first dose of fludarabine).</span></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If the patient experienced a previous Grade&nbsp;4 haemorrhagic
cystitis with cyclophosphamide, or demonstrated a chemorefractory state to a
cyclophosphamide&#8209;containing regimen administered shortly before
lymphodepleting chemotherapy, then the following should be used:</span></p>

<p class=Listlevel2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Bendamustine
(90&nbsp;mg/m<sup>2</sup> intravenous daily for 2&nbsp;days).</span></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>Lymphodepleting chemotherapy may be omitted
if a patient’s white blood cell (WBC) count is &#8804;1,000&nbsp;cells/µL
within 1&nbsp;week prior to Kymriah infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Pre&#8209;medication</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To minimise
potential acute infusion reactions, it is recommended that patients be pre&#8209;medicated
with paracetamol and diphenhydramine or another H1 antihistamine within
approximately 30 to 60&nbsp;minutes prior to Kymriah infusion. Corticosteroids
should not be used at any time except in the case of a life&#8209;threatening
emergency (see section&nbsp;4.4).</span></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Nottoc-headings style='margin:0in'><u><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Clinical
assessment prior to infusion</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah
treatment should be delayed in some patient groups at risk (see section&nbsp;4.4).</span></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Monitoring after infusion</span></u></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Patients should be monitored daily for the first
10&nbsp;days following infusion for signs and symptoms of potential cytokine
release syndrome, neurological events and other toxicities. Physicians should
consider hospitalisation for the first 10&nbsp;days post infusion</span><span
lang=EN-GB> or at the first signs/symptoms of </span><span lang=EN-GB>cytokine
release syndrome</span><span lang=EN-GB> and/or neurological events</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>After the first 10&nbsp;days following the
infusion, the patient should be monitored at the physician’s discretion.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Patients should be instructed to remain within
proximity (within 2&nbsp;hours of travel) of a qualified clinical facility for
at least 4&nbsp;weeks following infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>B-cell ALL</span></i><span lang=EN-GB>: No formal studies have been
performed in paediatric patients below 3&nbsp;years of age.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><i><span
lang=EN-GB style='font-size:11.0pt'>DLBCL</span></i><span lang=EN-GB
style='font-size:11.0pt'>: The safety and efficacy of Kymriah in children and
adolescents below 18&nbsp;years of age have not yet been established. No data
are available.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Elderly</span></u></i></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><i><span
lang=EN-GB style='font-size:11.0pt'>B&#8209;cell ALL</span></i><span
lang=EN-GB style='font-size:11.0pt'>: The safety and efficacy of Kymriah in
this population have not been established.</span></p>

<p class=Listlevel2 style='margin:0in;margin-bottom:.0001pt;text-indent:0in'><i><span
lang=EN-GB style='font-size:11.0pt'>DLBCL</span></i><span lang=EN-GB
style='font-size:11.0pt'>: No dose adjustment is required in patients over 65&nbsp;years
of age.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Patients seropositive for hepatitis B virus (HBV), hepatitis C virus
(HCV), or human immunodeficiency virus (HIV)</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience with manufacturing Kymriah for patients with a positive test for HIV,
active HBV, or active HCV infection. Leukapheresis material from these patients
will not be accepted for Kymriah manufacturing. </span><span lang=EN-GB>Screening
for HBV, HCV, and HIV must be performed in accordance with clinical guidelines
before collection of cells for manufacturing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah is for
intravenous use only.</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt'>Precautions to be taken before handling or
administering the medicinal product</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains genetically modified human blood cells. Healthcare
professionals handling Kymriah should take appropriate precautions (wearing
gloves and glasses) to avoid potential transmission of infectious diseases as
for any human-derived material.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Preparation for infusion</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Prior to Kymriah
infusion, it must be confirmed that the patient’s identity matches the
essential unique patient information on the infusion bag(s).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The timing of
thaw of Kymriah and infusion should be coordinated. </span><span lang=EN-GB>Please
refer to section&nbsp;6.6 for details on inspection and thawing of the infusion
bag. </span><span lang=EN-GB>The infusion start time should be confirmed in
advance and adjusted for thaw so that Kymriah is available for infusion when
the recipient is ready. Once Kymriah has been thawed and is at room temperature
</span><span lang=EN-GB>(20°C &#8209;25°C)</span><span lang=EN-GB>, it should
be infused within 30&nbsp;minutes to maintain maximum product viability,</span><span
lang=EN-GB> including any interruption during the infusion</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Administration</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah should
be administered as an intravenous infusion through latex&#8209;free intravenous
tubing without a leukocyte depleting filter, at approximately 10 to 20&nbsp;mL
per minute by gravity flow. All contents of the infusion bag(s) should be
infused. Sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection should be
used to prime the tubing prior to infusion and to rinse it after infusion. When
the full volume of Kymriah has been infused, the infusion bag should be rinsed
with 10 to 30&nbsp;mL sodium chloride 9&nbsp;mg/mL (0.9%) solution for
injection by back priming to ensure as many cells as possible are infused into
the patient.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If the volume of
Kymriah to be administered is &#8804;20&nbsp;mL, intravenous push may be used
as an alternative method of administration.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For special
precautions for disposal see section&nbsp;6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contraindications
of the lymphodepleting chemotherapy must be considered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4     Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>To ensure traceability the name
of the product, the batch number and the name of the treated patient should be
kept for a period of 30&nbsp;years.</p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Reasons to delay treatment</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Due to the risks associated with Kymriah treatment, infusion should
be delayed if a patient has any of the following conditions:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Unresolved serious adverse reactions
(especially pulmonary reactions, cardiac reactions or hypotension) from
preceding chemotherapies.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Active uncontrolled infection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Active graft&#8209;versus&#8209;host disease
(GVHD).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Significant clinical worsening of leukaemia
burden or rapid progression of lymphoma following lymphodepleting chemotherapy.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Blood, organ, tissue and
cell donation</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Patients treated with Kymriah should not donate blood,
organs, tissues or cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Active central nervous system (CNS) leukaemia or
lymphoma</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is limited
experience of use of Kymriah in patients with active CNS leukaemia </span><span
lang=EN-GB style='font-family:"TimesNewRomanPSMT,Times New Rom",serif'>and
active CNS lymphoma.</span><span lang=EN-GB> Therefore, the risk/benefit of
Kymriah has not been established in these populations.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Cytokine release syndrome</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytokine release
syndrome, including fatal or life&#8209;threatening events, has been frequently
observed after Kymriah infusion (see section&nbsp;4.8). In almost all cases,
development of cytokine release syndrome occurred between 1 to 10&nbsp;days (median
onset 3&nbsp;days) after Kymriah infusion</span><span lang=EN-GB>. The median
time to resolution of </span><span lang=EN-GB>cytokine release syndrome</span><span
lang=EN-GB> was 8&nbsp;days</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Symptoms of cytokine
release syndrome may include high fever, rigors, myalgia, arthralgia, nausea,
vomiting, diarrhoea, diaphoresis, rash, anorexia, fatigue, headache,
hypotension, dyspnoea, tachypnoea, and hypoxia. Organ dysfunction, including
cardiac insufficiency and arrhythmia, renal insufficiency and liver injury with
accompanying elevated aspartate aminotransferase (AST), elevated alanine
aminotransferase (ALT) or elevated total bilirubin may also be observed. In
some cases, disseminated intravascular coagulation (DIC) with low fibrinogen
levels, capillary leak syndrome (CLS), macrophage activation syndrome (MAS) and
haemophagocytic lymphohistiocytosis(HLH) may occur in the setting of cytokine
release syndrome. Patients should be closely monitored for signs or symptoms of
these events, including fever.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Risk factors for
severe cytokine release syndrome in paediatric and young adult B&#8209;cell ALL
patients are: high pre&#8209;infusion tumour burden, uncontrolled or
accelerating tumour burden following lymphodepleting chemotherapy, active
infection and early onset of fever or cytokine release syndrome following
Kymriah infusion. High tumour burden prior to Kymriah infusion was identified
as a risk factor for developing severe cytokine release syndrome in adult DLBCL
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In all
indications, appropriate prophylactic and therapeutic treatment for infections
should be provided, and complete resolution of any existing infections should
be ensured. Infections may also occur during cytokine release syndrome and may
increase the risk of a fatal event.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Management of cytokine release syndrome associated with Kymriah</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cytokine release
syndrome should be managed solely based on the patient’s clinical presentation
and according to the cytokine release syndrome management algorithm provided in
Table&nbsp;1. Anti&#8209;IL&#8209;6 based therapy such as tocilizumab has been
administered for moderate or severe cytokine release syndrome associated with
Kymriah. One dose of tocilizumab per patient must be on site and available for
administration prior to Kymriah infusion. The treatment centre should have
access to additional doses of tocilizumab within 8&nbsp;hours. Corticosteroids
may be administered in cases of life&#8209;threatening emergencies.
Tisagenlecleucel continues to expand and persist following administration of
tocilizumab and corticosteroids.</span><span lang=EN-GB> Patients with
medically significant cardiac dysfunction should be managed by standards of
critical care and measures such as echocardiography should be considered. </span><span
lang=EN-GB>Tumour necrosis factor (TNF) antagonists are not recommended for
management of Kymriah&#8209;associated cytokine release syndrome.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;1       Cytokine
release syndrome management algorithm</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.38%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="42%" style='width:42.22%;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Cytokine release syndrome severity</span></b></p>
  </td>
  <td width="57%" valign=top style='width:57.78%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Management</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="42%" valign=top style='width:42.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Prodromal syndrome</span></i></b><span lang=EN-GB>:</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Low&#8209;grade fever, fatigue, anorexia</span></p>
  </td>
  <td width="57%" valign=top style='width:57.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Observe in person; exclude infection; administer antibiotics per
  local guidelines if neutropenic; provide symptomatic support.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="42%" style='width:42.22%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Cytokine release syndrome requiring mild intervention &#8209; one
  or more of the following</span></i></b><span lang=EN-GB>:</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>High fever</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Hypoxia</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Mild hypotension</span></p>
  </td>
  <td width="57%" valign=top style='width:57.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Administer antipyretics, oxygen, intravenous fluids and/or low&#8209;dose
  vasopressors as needed.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="42%" valign=top style='width:42.22%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB>Cytokine release syndrome requiring moderate to aggressive
  intervention &#8209; one or more of the following</span></i></b><span
  lang=EN-GB>:</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Haemodynamic instability despite intravenous
  fluids and vasopressor support</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Worsening respiratory distress, including
  pulmonary infiltrates, increasing oxygen requirement including high&#8209;flow
  oxygen and/or need for mechanical ventilation</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Rapid clinical deterioration</span></p>
  </td>
  <td width="57%" valign=top style='width:57.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Administer high&#8209;dose or multiple
  vasopressors, oxygen, mechanical ventilation and/or other supportive care as
  needed.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Administer tocilizumab.</span></p>
  <p class=MsoNormal style='margin-left:29.3pt;text-indent:-14.35pt;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Patient weight less than 30&nbsp;kg:
  12&nbsp;mg/kg intravenously over 1&nbsp;hour</span></p>
  <p class=MsoNormal style='margin-left:29.3pt;text-indent:-14.35pt;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Patient weight &#8805;30&nbsp;kg: 8&nbsp;mg/kg
  intravenously over 1&nbsp;hour (maximum dose 800&nbsp;mg)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Repeat tocilizumab as needed at a minimum interval of 8&nbsp;hours
  if there is no clinical improvement.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>If no response to second dose of tocilizumab, consider a third
  dose of tocilizumab or pursue alternative measures for treatment of cytokine
  release syndrome.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Limit to a maximum total of 4&nbsp;tocilizumab doses.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>If no clinical improvement within 12 to
  18&nbsp;hours of the first tocilizumab dose, or worsening at any time,
  administer methylprednisolone 2&nbsp;mg/kg as an initial dose, then
  2&nbsp;mg/kg per day until vasopressors and high&#8209;flow oxygen are no
  longer needed, then taper.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Neurological adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Neurological events,
in particular encephalopathy, confusional state or delirium, occur frequently
with Kymriah and can be severe or life&#8209;threatening (see section&nbsp;4.8).
Other manifestations included</span><span lang=EN-GB> </span>depressed level of
consciousness, seizures, aphasia and speech disorder<span lang=EN-GB>. The
majority of neurological events occurred within 8&nbsp;weeks following Kymriah
infusion and were transient. The median time to onset of the first neurological
events was 8&nbsp;days in B&#8209;cell ALL and 6&nbsp;days in DLBCL. The median
time to resolution was 7&nbsp;days for B&#8209;cell ALL and 13&nbsp;days for
DLBCL. Neurological events can be concurrent with cytokine release syndrome,
following resolution of cytokine release syndrome or in the absence of cytokine
release syndrome.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients should
be monitored for neurological events. In case of neurological events, patients
should be diagnostically worked up and managed depending on the underlying
pathophysiology and in accordance with local standard of care.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Infections and febrile neutropenia</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
active, uncontrolled infection should not start Kymriah treatment until the
infection is resolved. Prior to Kymriah infusion, infection prophylaxis should
follow standard guidelines based on the degree of preceding immunosuppression.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Serious
infections, including life&#8209;threatening or fatal infections, occurred
frequently in patients after Kymriah infusion (see section&nbsp;4.8). Patients
should be monitored for signs and symptoms of infection and treated
appropriately. As appropriate, prophylactic antibiotics should be administered
and surveillance testing should be employed prior to and during treatment with
Kymriah. Infections are known to complicate the course and management of
concurrent </span><span lang=EN-GB>cytokine release syndrome.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Febrile
neutropenia was frequently observed in patients after Kymriah infusion (see
section&nbsp;4.8) and may be concurrent with </span><span lang=EN-GB>cytokine
release syndrome. In the event of febrile neutropenia, infection should be
evaluated and managed appropriately with broad&#8209;spectrum antibiotics,
fluids and other supportive care, as medically indicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients
achieving complete remission following Kymriah, resulting low immunoglobulin
levels can increase the risk for infections. Attention to signs and symptoms of
infection should be implemented according to age and standard specific guidelines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Prolonged cytopenias</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients may
continue to exhibit cytopenias for several weeks following lymphodepleting
chemotherapy and Kymriah infusion and should be managed according to standard guidelines.
The majority of patients who had cytopenias at day&nbsp;28 following Kymriah
treatment resolved to Grade&nbsp;2 or below within three months after treatment.
Prolonged neutropenia has been associated with increased risk of infection.
Myeloid growth factors, particularly granulocyte macrophage&#8209;colony
stimulating factor (GM&#8209;CSF), have the potential to worsen </span><span
lang=EN-GB>cytokine release syndrome symptoms and are not recommended during
the first 3&nbsp;weeks after Kymriah infusion or until cytokine release
syndrome has resolved.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Secondary malignancies</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients treated
with Kymriah may develop secondary malignancies or recurrence of their cancer. They
should be monitored life&#8209;long for secondary malignancies. In the event
that a secondary malignancy occurs, the company should be contacted to obtain
instructions on patient samples to collect for testing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hypogammaglobulinaemia</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypogammaglobulinaemia
and agammaglobulinaemia can occur in patients after Kymriah infusion. </span><span
lang=EN-GB>I</span><span lang=EN-GB>mmunoglobulin levels should be monitored
after treatment with Kymriah. In patients with low immunoglobulin levels pre&#8209;emptive
measures such as infection precautions, antibiotic prophylaxis and
immunoglobulin replacement should be taken according to age and standard guidelines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Tumour lysis syndrome (TLS)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>TLS, which may
be severe, has occasionally been observed. To minimise risk of TLS, patients
with elevated uric acid or high tumour burden should receive allopurinol, or an
alternative prophylaxis, prior to Kymriah infusion. Signs and symptoms of TLS
should be monitored and events managed according to standard guidelines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Concomitant disease</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with a
history of active CNS disorder or inadequate renal, hepatic, pulmonary or
cardiac function were excluded from the studies. These patient are likely to be
more vulnerable to the consequences of the adverse reactions described below
and require special attention.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Prior stem cell transplantation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not
recommended that patients receive Kymriah within 4&nbsp;months of undergoing an
allogeneic stem cell transplant (SCT) because of the potential risk of Kymriah
worsening GVHD. Leukapheresis for Kymriah manufacturing should be performed at
least 12&nbsp;weeks after allogeneic SCT.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Serological testing</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is
currently no experience with manufacturing Kymriah for patients testing
positive for HBV, HCV and HIV.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Screening for
HBV, HCV and HIV must be performed in accordance with clinical guidelines
before collection of cells for manufacturing.</span><span lang=EN-GB> Hepatitis
B virus (HBV) reactivation, can occur in patients treated with medicinal
products directed against B cells and could result in fulminant hepatitis,
hepatic failure and death.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><u><span lang=EN-GB style='font-size:11.0pt'>Prior treatment with anti&#8209;CD19
therapy</span></u></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>There is limited experience with Kymriah in
patients exposed to prior CD19&#8209;directed therapy. Kymriah is not
recommended if the patient has relapsed with CD19&#8209;negative leukaemia
after prior anti&#8209;CD19 therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Interference with serological testing</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to limited
and short spans of identical genetic information between the lentiviral vector
used to create Kymriah and HIV, some commercial HIV nucleic acid tests (NAT)
may give a false positive result.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='page-break-after:avoid'><u><span style='font-size:11.0pt'>Sodium
and potassium content</span></u></p>

<p class=Default style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>This medicinal product contains 24.3 to 121.5&nbsp;mg sodium
per dose, equivalent to 1 to 6% of the WHO recommended maximum daily intake of
2&nbsp;g sodium for an adult.</p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>&nbsp;</p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'>This medicinal product contains potassium, less than
1&nbsp;mmol (39&nbsp;mg) per dose, i.e. essentially “potassium&#8209;free”.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
page-break-after:avoid;text-autospace:none'><u><span lang=EN-GB>Content of
dextran 40 and dimethyl sulfoxide (DMSO)</span></u></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
page-break-after:avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product contains 11&nbsp;mg dextran 40 and 82.5&nbsp;mg dimethyl sulfoxide
(DMSO) per mL. Each of these excipients are known to possibly cause
anaphylactic reaction following parenteral administration. Patients not
previously exposed to dextran and DMSO should be observed closely during the
first minutes of the infusion period.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5     Interaction with
other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:white'>No pharmacokinetic or pharmacodynamic drug
interaction studies with tisagenlecleucel have been performed</span><span
lang=EN-GB>. </span>The co&#8209;administration of agents known to inhibit T&#8209;cell
function has not been formally studied. Administration of low&#8209;dose
steroids as per the cytokine release syndrome treatment algorithm does not
impact the expansion and persistence of CAR&#8209;T cells. The co&#8209;administration
of agents known to stimulate T&#8209;cell function has not been investigated
and the effects are unknown.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Live vaccines</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety of
immunisation with live vaccines during or following Kymriah treatment has not
been studied. Vaccination with live vaccines is not recommended for at least
6&nbsp;weeks prior to the start of lymphodepleting chemotherapy, during Kymriah
treatment, and until immune recovery following treatment with Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6     </span></b><b><span
lang=EN-GB>Fertility, p</span></b><b><span lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Women of childbearing potential/Contraception in males and females</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pregnancy status
for females of child&#8209;bearing age should be verified prior to starting
treatment with Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See the
prescribing information for lymphodepleting chemotherapy for information on the
need for effective contraception in patients who receive the lymphodepleting
chemotherapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are insufficient
exposure data to provide a recommendation concerning duration of contraception
following treatment with Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data from the use of Kymriah in pregnant women. No animal studies have been
conducted with Kymriah to assess whether it can cause foetal harm when
administered to a pregnant woman (see section&nbsp;5.3). It is not known
whether Kymriah has the potential to be transferred to the foetus via the
placenta and could cause foetal toxicity, including B&#8209;cell
lymphocytopenia. Kymriah is not recommended during pregnancy and in women of
childbearing potential not using contraception.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pregnant women
should be advised on the potential risks to the foetus. Pregnancy after Kymriah
therapy should be discussed with the treating physician. Pregnant women who
have received Kymriah may have hypogammaglobulinaemia. Assessment of
immunoglobulin levels is indicated in newborns of mothers treated with Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether Kymriah cells are excreted in human milk. A risk to the breast&#8209;fed
infant cannot be excluded. Women who are breast&#8209;feeding should be advised
of the potential risk to the breast&#8209;fed infant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Following administration
of Kymriah, breast&#8209;feeding should be discussed with the treating
physician.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data on the effect of Kymriah on fertility. Effects of Kymriah on male and
female fertility have not been evaluated in animal studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7     Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah has major
influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
potential for neurological events, including altered mental status or seizures,
patients receiving Kymriah are at risk for altered or decreased consciousness
or coordination in the 8&nbsp;weeks following infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Safety
assessment was based on a total of 194&nbsp;patients (with paediatric and young
adult B-cell ALL and DLBCL) who received Kymriah in two multi-centre pivotal
clinical studies.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>B&#8209;cell ALL</span></u></i></p>

<p class=Text style='margin-top:0in'><span lang=EN-GB style='font-size:11.0pt'>The
adverse reactions described in this section were characterised in 79&nbsp;patients
infused with Kymriah in the multi-centre, pivotal clinical study CCTL019B2202.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The most common non&#8209;haematological adverse reactions were
cytokine release syndrome (77%), infections (73%), hypogammaglobulinaemia (53%),
pyrexia (42%) and decreased appetite (38%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The most common haematological adverse reactions were decreased
white blood cells (100%), decreased haemoglobin (100%), decreased neutrophils
(100%), decreased lymphocytes (100%) and decreased platelets (97%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Grade&nbsp;3 and 4 adverse reactions were reported in 89% of
patients. The most common Grade&nbsp;3 and 4 non&#8209;haematological adverse
reaction was </span><span lang=EN-GB>cytokine release syndrome (48%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The most common Grade&nbsp;3 and 4 haematological laboratory
abnormalities were white blood cells decreased (97%), lymphocytes decreased
(96%), neutrophils decreased (95%), platelets decreased (77%) and haemoglobin
decreased (48%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Grade&nbsp;3 and 4 adverse reactions were more often observed within
the initial 8&nbsp;weeks post&#8209;infusion (82% of patients) compared to
after 8&nbsp;weeks post&#8209;infusion (51% of patients).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>DLBCL</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The adverse reactions described in this section were characterised in
115&nbsp;patients </span><span lang=EN-GB>infused </span><span lang=EN-GB>with
Kymriah in one global multicentre international study, i.e. the ongoing pivotal
clinical study CCTL019C2201.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The most common non&#8209;haematological adverse reactions were </span><span
lang=EN-GB>cytokine release syndrome</span><span lang=EN-GB> (57%), infections
(58%), pyrexia (35%), diarrhoea (31%), nausea (29%), fatigue (27%) and hypotension
(25%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>The most
common haematological adverse reactions were decreased lymphocytes (100%),
decreased white blood cells (99%), decreased haemoglobin (99%), decreased
neutrophils (97%), and decreased platelets (95%).</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Grade&nbsp;3 and 4 adverse reactions were reported in 88% of
patients. The most common Grade&nbsp;3 and 4 non&#8209;haematological adverse
reactions were infections (34%) and </span><span lang=EN-GB>cytokine release
syndrome</span><span lang=EN-GB> (23%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The most common (&gt;25%) Grade&nbsp;3 and 4 haematological
laboratory abnormalities were </span><span lang=EN-GB>lymphocyte count</span><span
lang=EN-GB> decreased (95%), </span><span lang=EN-GB>neutrophil count decreased</span><span
lang=EN-GB> (82%), </span><span lang=EN-GB>white blood cell count decreased</span><span
lang=EN-GB> (78%), </span><span lang=EN-GB>haemoglobin decreased</span><span
lang=EN-GB> (59%) and </span><span lang=EN-GB>platelet count decreased</span><span
lang=EN-GB> (56%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Grade&nbsp;3 and 4 adverse reactions were more often observed within
the initial 8&nbsp;weeks post&#8209;infusion (82%) compared to after
8&nbsp;weeks post&#8209;infusion (48%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Tabulated list of adverse drug reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The adverse reactions described in this section were identified in 79
and 115&nbsp;patients in the ongoing multicentre pivotal clinical studies (CCTL019B2202
and CCTL019C2201). Adverse drug reactions from these clinical studies (Table&nbsp;2)
are listed by MedDRA system organ class. Within each system organ class, the
adverse drug reactions are ranked by frequency, with the most frequent
reactions first,</span> using the following convention: very common
(&#8805;1/10); common (&#8805;1/100 to &lt;1/10); uncommon (&#8805;1/1,000 to
&lt;1/100); rare (&#8805;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000);
not known (cannot be estimated from the available data)<span lang=EN-GB>.
Within each frequency grouping, adverse drug reactions are presented in order
of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Table&nbsp;2       Adverse
drug reactions observed in clinical studies</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="17%" rowspan=2 valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>Adverse drug reaction (MedDRA
  system organ class)</span></b></p>
  </td>
  <td width="82%" colspan=3 style='width:82.14%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><b><span lang=DE-CH style='font-family:"Times New Roman",serif'>Studies
  B2202 (</span></b><b><span lang=DE-CH style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>N=</span></b><b><span lang=DE-CH style='font-family:
  "Times New Roman",serif'>79) + C2201 (</span></b><b><span lang=DE-CH
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>N</span></b><b><span
  lang=DE-CH style='font-family:"Times New Roman",serif'>=115)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="29%" style='width:29.74%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Very
  common</span></b></p>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>(&#8805;1/10)</span></b></p>
  </td>
  <td width="28%" style='width:28.32%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></b></p>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>(&#8805;1/100
  to &lt;1/10)</span></b></p>
  </td>
  <td width="24%" style='width:24.08%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></b></p>
  <p class=Table align=center style='margin:0in;text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>(&#8805;1/1000
  to &lt;1/100)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Infections
  and infestations<sup>1)</sup></span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Infections &#8209; pathogen unspecified</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Viral infections</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Bacterial infections</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Fungal infections</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Blood
  and lymphatic system disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Anaemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Haemorrhage<sup>2)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Febrile neutropenia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Neutropenia</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Thrombocytopenia</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Haemophagocytic lymphohistiocytosis</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Leukopenia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Pancytopenia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Coagulopathy</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Lymphopenia</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>B-cell aplasia</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Immune
  system disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Cytokine release syndrome</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypogammaglobulinaemia<sup>3)</sup></span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Infusion&#8209;related reaction</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Graft&#8209;versus&#8209;host disease</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Decreased appetite</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypokalaemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypophosphataemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypomagnesaemia</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Hypocalcaemia</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypoalbuminaemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hyperglycaemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hyponatraemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hyperuricaemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Fluid overload</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypercalcaemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Tumour lysis syndrome</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hyperkalaemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hyperphosphataemia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypernatraemia</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Hypermagnesaemia</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Psychiatric
  disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Anxiety</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Delirium<sup>4)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Sleep disorder<sup>5)</sup></span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Nervous
  system disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Headache<sup>6)</sup></span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Encephalopathy<sup>7)</sup></span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Dizziness<sup>8)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Peripheral neuropathy<sup>9)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Tremor<sup>10)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Motor dysfunction<sup>11)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Seizure<sup>12)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Speech disorders<sup>13)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Neuralgia<sup>14)</sup></span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Ataxia<sup>15)</sup></span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Ischaemic cerebral infarction</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Eye
  disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Visual impairment<sup>16)</sup></span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Cardiac
  disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Arrhythmia<sup>17)</sup></span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Cardiac failure<sup>18)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Cardiac arrest</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Vascular
  disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypotension<sup>19)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hypertension</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Thrombosis<sup>20)</sup></span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Capillary leak syndrome</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Flushing</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Respiratory,
  thoracic and mediastinal disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Cough<sup>21)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Dyspnoea<sup>22)</sup></span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Hypoxia</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Oropharyngeal pain<sup>23)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Pulmonary oedema<sup>24)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Nasal congestion</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Pleural effusion</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Tachypnoea</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Acute respiratory distress syndrome</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Lung infiltration</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Diarrhoea</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Nausea</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Vomiting</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Constipation</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Abdominal pain<sup>25)</sup></span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Stomatitis</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Abdominal distension</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Dry mouth</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Ascites</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif'>Hepatobiliary
  disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hyperbilirubinaemia</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Skin
  and subcutaneous tissue disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Rash<sup>26)</sup></span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Pruritus</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Erythema</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Hyperhidrosis</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Night sweats</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Arthralgia</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Back pain</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Myalgia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Musculoskeletal pain</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Renal
  and urinary disorders</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Acute kidney injury<sup>27)</sup></span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>General
  disorders and administration site conditions</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=FR-CH style='font-family:"Times New Roman",serif;
  color:black'>Pyrexia</span></p>
  <p class=Table style='margin:0in'><span lang=FR-CH style='font-family:"Times New Roman",serif;
  color:black'>Fatigue<sup>28)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=FR-CH style='font-family:"Times New Roman",serif;
  color:black'>Oedema<sup>29)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=FR-CH style='font-family:"Times New Roman",serif;
  color:black'>Pain<sup>30)</sup></span></p>
  <p class=Table style='margin:0in'><span lang=FR-CH style='font-family:"Times New Roman",serif;
  color:black'>Chills</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Influenza&#8209;like illness</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Asthenia</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Multiple organ dysfunction syndrome</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Investigations</span></p>
  </td>
  <td width="29%" valign=top style='width:29.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Lymphocyte count decreased*</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>White blood cell count decreased*</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Haemoglobin decreased*</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Neutrophil count decreased*</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Platelet count decreased*</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Aspartate aminotransferase increased</span></p>
  </td>
  <td width="28%" valign=top style='width:28.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Alanine aminotransferase increased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Blood bilirubin increased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Weight decreased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Serum ferritin increased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Blood fibrinogen decreased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>International normalised ratio increased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Fibrin D dimer increased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Activated partial thromboplastin time prolonged</span></p>
  <p class=Table style='margin:0in'><span style='font-family:"Times New Roman",serif;
  color:black'>Blood alkaline phosphatase increased</span></p>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>Prothrombin time prolonged</span></p>
  </td>
  <td width="24%" valign=top style='width:24.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:16.55pt'>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.55pt'>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>1)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>          Infections and
  infestations presented reflect high&#8209;level group terms.</span></p>
  <p class=Legend style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>2)</span></sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>          Haemorrhage
  includes anal haemorrhage, blood urine present, catheter site haemorrhage,
  cerebral haemorrhage, conjunctival haemorrhage, contusion, cystitis
  haemorrhagic, duodenal ulcer haemorrhage, disseminated intravascular
  coagulation, epistaxis, eye contusion, gastrointestinal haemorrhage, gingival
  bleeding, haematochezia, haemarthrosis, haematemesis, haematuria,
  haemoptysis, large intestinal haemorrhage, melaena, menorrhagia, mouth
  haemorrhage, peritoneal haematoma, petechiae, pharyngeal haemorrhage, post&#8209;procedural
  haemorrhage, pulmonary haemorrhage, purpura, retinal haemorrhage, traumatic
  haematoma, tumour haemorrhage, upper gastrointestinal haemorrhage and vaginal
  haemorrhage.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>3)               </span></sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Hypogammaglobulinaemia
  includes immunoglobulins decreased, blood immunoglobulin A decreased, blood
  immunoglobulin G decreased, blood immunoglobulin M decreased,
  immunodeficiency, immunodeficiency common variable and
  hypogammaglobulinaemia.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>4)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>          Delirium includes
  agitation, delirium, hallucination, hallucination visual, irritability and
  restlessness.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>5)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>          Sleep disorder includes
  sleep disorder, insomnia and nightmare.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>6)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>          Headache includes
  headache and migraine.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>7)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>          Encephalopathy includes
  depressed level of consciousness, mental status changes, automatism,
  cognitive disorder, confusional state, disturbance in attention,
  encephalopathy, somnolence, lethargy, memory impairment, metabolic
  encephalopathy and thinking abnormal.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>8)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>          Dizziness includes
  dizziness, presyncope and syncope.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>9)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>          Peripheral neuropathy
  includes paraesthesia, peripheral sensory neuropathy, neuropathy peripheral,
  hyperaesthesia and hypoaesthesia.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>10)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Tremor includes
  dyskinesia and tremor.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>11)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Motor dysfunction
  includes muscle spasms, muscle twitching, myoclonus and myopathy.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>12)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Seizure includes seizure,
  generalised tonic&#8209;clonic seizures and status epilepticus.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>13)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Speech disorders includes
  speech disorders, dysarthria and aphasia.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>14)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Neuralgia includes
  neuralgia and sciatica.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>15)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Ataxia includes ataxia
  and dysmetria.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>16)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Visual impairment
  includes vision blurred and visual impairment.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>17)             </span></sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>Arrhythmia
  includes atrial fibrillation, supraventricular tachycardia, </span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>tachycardia and
  ventricular extrasystoles.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>18)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Cardiac failure includes
  cardiac failure, left ventricular dysfunction, cardiac failure congestive and
  right ventricular dysfunction.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>19)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Hypotension includes
  hypotension and orthostatic hypotension.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>20)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Thrombosis includes deep
  vein thrombosis, embolism, pulmonary embolism, thrombosis, vena cava
  thrombosis and venous thrombosis.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>21)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Cough includes cough,
  productive cough and upper&#8209;airway cough syndrome.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>22)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        <span style='color:black'>Dyspnoea
  includes dyspnoea, dyspnoea exertional, respiratory distress and respiratory
  failure.</span></span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>23)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Oropharyngeal pain
  includes oral pain and oropharyngeal pain.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>24)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Pulmonary oedema includes
  acute pulmonary oedema and pulmonary oedema</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>25)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Abdominal pain includes
  abdominal pain, abdominal pain upper and abdominal discomfort.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>26)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Rash includes dermatitis,
  dermatitis acneiform, dermatitis contact,</span><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>rash, rash maculo&#8209;papular,
  rash papular and rash pruritic.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>27)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Acute kidney injury
  includes acute kidney injury, anuria, azotaemia, blood creatinine abnormal,</span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'> </span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>blood creatinine
  increased, renal failure, renal tubular dysfunction and renal tubular
  necrosis.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:30.05pt;text-indent:-28.35pt'><sup><span lang=FR-CH
  style='font-family:"Times New Roman",serif'>28)</span></sup><span lang=FR-CH
  style='font-family:"Times New Roman",serif'>        Fatigue includes fatigue
  and malaise.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:30.05pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>29)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        <span style='color:black'>Oedema
  includes oedema peripheral, generalised oedema, localised oedema, face oedema
  and peripheral swelling.</span></span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:30.05pt;text-indent:-28.35pt'><sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>30)</span></sup><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>        Pain includes pain and
  pain in extremity.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt'>*        <span style='font-family:
  "Times New Roman",serif'>Frequency is based on laboratory values. Patients
  are counted only for the worst grade observed post baseline.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Description of selected adverse drug reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Cytokine release syndrome</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the ongoing clinical study in paediatric and young adult B&#8209;cell
ALL (N=79), </span><span lang=EN-GB>cytokine release syndrome</span><span
lang=EN-GB> was reported in 77% of patients (48% with Grade&nbsp;3 or 4). Two
deaths occurred within 30&nbsp;days of tisagenlecleucel infusion, including one
patient, who died from progressive leukaemia in the setting of possible cytokine
release syndrome and one patient who experienced fatal intracranial haemorrhage
that developed during the course of resolved </span><span lang=EN-GB>cytokine
release syndrome,</span><span lang=EN-GB> abdominal compartment syndrome,
coagulopathy and renal failure.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the ongoing clinical study in DLBCL (N=115), </span><span
lang=EN-GB>cytokine release syndrome</span><span lang=EN-GB> was reported in 57%
of patients (23% with Grade&nbsp;3 or 4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Cytokine release syndrome</span><span lang=EN-GB> was graded with
the Penn scale as follows: Grade&nbsp;1:&nbsp;mild reactions, reactions
requiring supportive care; Grade&nbsp;2:&nbsp;moderate reactions, reactions
requiring intravenous therapies; Grade&nbsp;3:&nbsp;severe reactions, reactions
requiring low&#8209;dose vasopressors or supplemental oxygen;
Grade&nbsp;4:&nbsp;life&#8209;threatening reactions, those requiring high&#8209;dose
vasopressors or intubation; Grade&nbsp;5:&nbsp;death.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For clinical management of </span><span lang=EN-GB>cytokine release
syndrome</span><span lang=EN-GB>, see section&nbsp;4.4 and Table&nbsp;1.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Infections and febrile neutropenia</span></u></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>In B&#8209;cell ALL
patients severe infections (Grade&nbsp;3 and higher), which can be life&#8209;threatening
or fatal, occurred in 48% of patients after Kymriah infusion. The overall
incidence (all grades) was 73% (unspecified 57%, viral 38%, bacterial 27% and
fungal 15%) (see section&nbsp;4.4). 43% of the patients experienced an
infection of any type within 8&nbsp;weeks after Kymriah infusion.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:black'>In DLBCL patients </span><span lang=EN-GB
style='color:black'>severe </span><span lang=EN-GB>infections (Grade&nbsp;3 and
higher), which can be life&#8209;threatening or fatal, occurred in 34% of
patients. The overall incidence (all grades) was 58% (unspecified 48%, bacterial
15%, fungal 11% and viral 11%) (see section&nbsp;4.4). 37% of the patients
experienced an infection of any type within 8&nbsp;weeks.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Severe febrile neutropenia (Grade&nbsp;3 or 4) was observed in 34%
of paediatric and young adult B&#8209;cell ALL patients and 17% of DLBCL
patients. See section&nbsp;4.4 for the management of febrile neutropenia before
and after Kymriah infusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Prolonged cytopenias</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Cytopenias are very common based on prior chemotherapies and Kymriah
therapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>All paediatric and young adult B&#8209;cell ALL patients had a Grade&nbsp;3
or 4 cytopenia at </span><span class=MsoCommentReference><span lang=EN-GB>some</span></span><span
lang=EN-GB> time after Kymriah infusion. Grade&nbsp;3 and 4 cytopenias not
resolved by day&nbsp;28 after Kymriah infusion based on laboratory findings
included decreased count of white blood cells (57%), neutrophils (54%), lymphocytes
(44%), and thrombocytes (42%) and decreased haemoglobin (13%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>All adult DLBCL patients had Grade&nbsp;3 and 4 cytopenias at some time
after Kymriah infusion. Grade&nbsp;3 and 4 cytopenias not resolved by day&nbsp;28
based on laboratory findings included decreased count of thrombocytes (39%),
lymphocytes (29%), neutrophils (25%), and white blood cells (21%) and decreased
haemoglobin (14%).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Neurological adverse reactions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The majority of neurotoxic events occurred within 8&nbsp;weeks
following infusion and were transient.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In paediatric and young adult B&#8209;cell ALL patients, manifestations
of encephalopathy and/or delirium occurred in 39% of patients (10% were Grade&nbsp;3
or 4) within 8&nbsp;weeks after Kymriah infusion. In DLBCL patients, manifestations
of encephalopathy and/or delirium occurred in 20% of patients (11% were Grade&nbsp;3
or 4) within 8&nbsp;weeks after Kymriah infusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Hypogammaglobulinaemia</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hypogammaglobulinaemia was reported in 53% of patients treated with
Kymriah for r/r ALL and 17% of patients with r/r DLBCL.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pregnant women who have received Kymriah may have
hypogammaglobulinaemia. Immunoglobulin levels should be assessed in newborns of
mothers treated with Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Immunogenicity</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In clinical studies, humoral immunogenicity of tisagenlecleucel was
measured by determination of anti&#8209;murine CAR19 antibodies (anti&#8209;mCAR19)
in serum pre&#8209; and post&#8209;administration. The majority of patients
tested positive for pre&#8209;dose anti&#8209;mCAR19 antibodies in paediatric
and young adult ALL (B2202, 91.1%) and adult DLBCL (C2201, 93.9%) patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Treatment&#8209;induced anti&#8209;mCAR19 antibodies were found in 40.5%
of paediatric and young adult ALL and 8.7% of adult DLBCL patients. Pre&#8209;existing
and treatment&#8209;induced antibodies were not associated with an impact on
clinical response nor did they have an impact on the expansion and persistence
of tisagenlecleucel. There is no evidence that the presence of pre&#8209;existing
and treatment&#8209;induced anti&#8209;mCAR19 antibodies impacts the safety or
effectiveness of Kymriah.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>T&#8209;cell immunogenicity responses were not observed in paediatric
and young adult B&#8209;cell ALL and adult r/r DLBCL patients.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='color:black;
background:#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacotherapeutic group: </span><span lang=EN-GB>other
antineoplastic agents, ATC code: L01XX71<span style='color:black;background:
#D9D9D9'>.</span></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='color:#262626'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='color:#262626'>Tisagenlecleucel</span><span lang=EN-GB> is an
autologous, immunocellular cancer therapy which involves reprogramming a
patient’s own T cells with a transgene encoding a chimeric antigen receptor
(CAR) to identify and eliminate CD19 expressing cells. The CAR is comprised of
a murine single chain antibody fragment which recognises CD19 and is fused to
intracellular signalling domains from 4&#8209;1BB (CD137) and CD3 zeta. The CD3
zeta component is critical for initiating T&#8209;cell activation and anti-tumour
activity, while 4&#8209;1BB enhances the expansion and persistence of tisagenlecleucel.
Upon binding to CD19&#8209;expressing cells, the CAR transmits a signal promoting
T&#8209;cell expansion and persistence of tisagenlecleucel.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Acute lymphoblastic leukaemia (ALL)</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of Kymriah treatment in paediatric and young
adult patients up to and including 25&nbsp;years of age, with relapsed or
refractory (r/r) B-cell ALL were evaluated in a total of 203&nbsp;patients in
one pivotal (B2202, N=79) and two supportive (B2205J, N=64, and B2101J, N=60) open&#8209;label,
single&#8209;arm phase I/II studies. All patients had leukapheresis products
collected and cryopreserved prior to or during study entry.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pivotal study B2202 (ELIANA) is a multicentre, single&#8209;arm
phase II study in paediatric and young adult patients with r/r B-cell ALL. Of 97&nbsp;patients
enrolled, 79 received infusion with Kymriah; for 8&nbsp;patients (8%) Kymriah
could not be manufactured; reasons for discontinuation prior to Kymriah
infusion included death (n=7; 7%) or adverse events (n=3; 3%) while awaiting
Kymriah manufacturing in the clinical study. The median duration of study
follow-up defined as the time from Kymriah infusion to the date of completion
or discontinuation from follow-up prior to the data cut-off date was 16.0&nbsp;months
(range: 0.4-34.4). The median time from Kymriah infusion to the data cut-off
date was 24.2&nbsp;months (range: 4.5-35.1). The study is still ongoing.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Key baseline information for enrolled and infused patients is
presented in Table&nbsp;3. </span><span lang=EN-GB>The majority of patients </span><span
lang=EN-GB>(69/79, 87%) </span><span lang=EN-GB>received bridging therapy while
waiting for Kymriah. </span><span lang=EN-GB>A total of 76 out of 79&nbsp;patients
(96%) who received Kymriah infusion also received lymphodepleting chemotherapy
after enrolment and prior to infusion of a single dose of Kymriah (see section&nbsp;4.2
for condition of lymphodepleting chemotherapy).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-align:left;text-indent:-56.7pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Table&nbsp;3       Study
B2202: Baseline information across the enrolled and the infused patient
population</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:29.4pt'>
   <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
   border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width="25%" valign=top style='width:25.72%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Enrolled</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>N=97</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>n
   (%)</b></p>
   </td>
   <td width="25%" valign=top style='width:25.74%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Infused</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>N=79</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>n
   (%)</b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Age
  (years)</b></p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Mean
  (standard deviation)</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>12 (5.48)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>12 (5.38)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Median
  (minimum – maximum)</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>11 (3 –
  27)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>11 (3 –
  24)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Age
  category (years) - n (%)</b></p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          &lt;10&nbsp;years</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>40
  (41.2)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>32
  (40.5)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          &#8805;10&nbsp;years
  and &lt;18&nbsp;years</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>40
  (41.2)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>33
  (41.8)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          &#8805;18&nbsp;years</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>17 (17.5)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>14
  (17.7)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Sex -
  n (%)</b></p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Male</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>54 (55.7)
  </p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>45
  (57.0)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Female</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>43 (44.3)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>34 (43)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'><b>Disease status (%)</b></p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>          Primary refractory<sup>1</sup></p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>8 (8.2)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>6 (7.6)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>          Relapsed disease<sup>2</sup></p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>89 (91.8)</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>73 (92.4)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Prior
  stem-cell transplantation - n (%)</b></p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          0</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>39 (40.2)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>31
  (39.2)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          1</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50 (51.5)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>42
  (53.2)</p>
  </td>
 </tr>
 <tr>
  <td width="48%" valign=top style='width:48.54%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          2</p>
  </td>
  <td width="25%" valign=top style='width:25.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>8 (8.2)</span></p>
  </td>
  <td width="25%" valign=top style='width:25.74%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>6 (7.6)</p>
  </td>
 </tr>
 <tr style='height:18.25pt'>
  <td width="100%" colspan=3 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><sup>1</sup>Primary
  refractory: Never had a morphologic complete remission (CR) prior to the
  study;</p>
  <p class=MsoNormal style='line-height:normal'><sup>2</sup>Relapsed disease:
  Had at least one relapse prior to the study</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Efficacy was established through the primary endpoint of overall
remission rate (ORR), which includes best overall response as complete
remission (CR) or complete remission with incomplete blood count recovery (CRi)
within 3&nbsp;months post infusion, as determined by Independent Review
Committee (IRC) assessment, as well as secondary endpoints including duration
of remission (DOR) and the proportion of patients who achieved CR or CRi with
minimal residual disease (MRD) &lt;0.01% by flow cytometry (MRD&#8209;negative).</span><span
lang=EN-GB> See Table&nbsp;4 for efficacy results from this study. ORR was
consistent across all subgroups. Eight </span><span lang=EN-GB>patients (10.1%)
who achieved CR/CRi after Kymriah infusion went to haematopoietic stem cell transplant
while in remission of which 6 of the patients (7.6%) proceeded to transplant
within the first 6&nbsp;months post&#8209;infusion while in remission</span><span
lang=EN-GB>. Kymriah was administered in a qualified Kymriah treatment centre
in an inpatient and outpatient setting.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Table&nbsp;4       Study
B2202: Efficacy results in paediatric and young adult patients with
relapsed/refractory B&#8209;cell acute lymphoblastic leukaemia (ALL)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:12.9pt'>
  <td width=332 style='width:249.15pt;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Primary endpoint</span></b></p>
  </td>
  <td width=152 style='width:113.85pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Enrolled patients</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=97</span></b></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Infused patients</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=79</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Overall
  remission rate (ORR)<sup>1,2</sup>, n (%)</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>95% CI</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>65 (67.0)</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>(56.7,
  76.2)</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>p&lt;0.0001</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>65
  (82.3)</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>(72.1,
  90.0)</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>p&lt;0.0001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>     CR<sup>3</sup>,
  n (%)</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>49 (50.5)</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>49
  (62.0)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>     CRi<sup>4</sup>,
  n (%)</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>16 (16.5)</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>16 (20.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Key secondary endpoint</span></b></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=97</span></b></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=79</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>CR
  or CRi with MRD negative bone marrow<sup>5,6</sup>, n (%)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='color:black'>95% CI</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>64 (66.0)</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>(55.7,
  75.3)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB style='color:black'>p&lt;0.0001</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>64
  (81.0)</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>(70.6,
  89.0)</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>p&lt;0.0001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Duration of
  remission (DOR)</span></b><sup><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>7</span></sup></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>N=65</span></b></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>N=65</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>%
  event free probability at 12&nbsp;months</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>66.3</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>66.3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>%
  event free probability at 18&nbsp;months</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>66.3</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>66.3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Median
  (months) (95% CI)</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Not
  reached (20.0, NE<sup>9</sup>)</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Not
  reached (20.0, NE)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Other secondary endpoint</span></b></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=97</span></b></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=79</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Overall
  survival (OS)<sup>8</sup></span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>     %
  survival probability at 12&nbsp;months</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>69.8</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>76.4</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:14.2pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Times New Roman",serif;color:black'>% survival probability
  at 24&nbsp;months</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>56.9</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>66.3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=332 valign=top style='width:249.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>     Median
  (months) (95% CI)</span></p>
  </td>
  <td width=152 valign=top style='width:113.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Not
  reached (19.4, NE)</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Not
  reached (28.2, NE)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>1</span></sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:black'>        Requires remission
  status to be maintained for at least 28&nbsp;days without clinical evidence
  of relapse.</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>2</span></sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:black'>        Nominal one&#8209;sided
  exact p&#8209;value based on H0: ORR &#8804;20% vs. Ha: ORR &gt;20%</span></p>
  <p class=MsoCommentText style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><sup><span lang=EN-GB style='font-size:11.0pt;
  color:black'>3</span></sup><span lang=EN-GB style='font-size:11.0pt;
  color:black'>        CR (complete remission) was defined as &lt;5% of blasts
  in the bone marrow, circulating blasts in blood should be &lt;1%, no evidence
  of extramedullary disease, and full recovery of peripheral blood counts
  (platelets &gt;100,000/&#956;L and absolute neutrophil counts [ANC]
  &gt;1,000/&#956;L) without blood transfusion.</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>4</span></sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:black'>        CRi (complete
  remission with incomplete blood count recovery) was defined as &lt;5% of
  blasts in the bone marrow, circulating blasts in blood should be &lt;1%, no
  evidence of extramedullary disease, and without full recovery of peripheral
  blood counts with or without blood transfusion.</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>5</span></sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:black'>        MRD (minimal
  residual disease) negative was defined as MRD by flow cytometry &lt;0.01%.</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>6</span></sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:black'>        Nominal one&#8209;sided
  exact p&#8209;value based on H0: Rate of MRD negative remission &#8804;15%
  vs. Ha:&nbsp;&gt;15%.</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>7</span></sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:black'>        DOR was defined as
  time since onset of CR or CRi to relapse or death due to underlying
  indication, whichever is earlier (N=65).</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>8</span></sup><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:black'>        OS was defined as
  time from date of Kymriah infusion to the date of death due to any cause for
  infused patients and from time of date of enrolment to the date of death due
  to any cause for enrolled patients.</span></p>
  <p class=Table style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>9                 </span></sup><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Not
  estimable</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Health&#8209;related quality of life (HRQoL) was evaluated by PedsQL
and EQ&#8209;5D questionnaires completed by patients aged 8&nbsp;years and
above (n=61). Among patients responding (n=51), the mean</span><u><span
lang=EN-GB> </span></u><span lang=EN-GB>(SD) change from baseline in the PedsQL
total score was 13.1 (13.45) at month&nbsp;3, 15.4 (16.81) at month&nbsp;6 and
25.0 (19.09) at month&nbsp;12, and the mean (SD) change from baseline in the EQ&#8209;5D
VAS score was 16.0 (16.45) at month&nbsp;3, 15.3 (18.33) at month&nbsp;6 and </span><span
lang=EN-GB style='color:black'>21.7 (17.14) at month&nbsp;12</span><span
lang=EN-GB>, indicating overall clinically meaningful improvement in HRQoL </span><span
lang=EN-GB>following Kymriah infusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The supportive study B2205J (ENSIGN) was a multicentre single-arm phase&nbsp;II
study in paediatric and young adult patients with r/r B&#8209;cell ALL. The
study had similar study design and enrolled comparable patient populations as
the pivotal study B2202. The main difference between the two studies was the
definition of the primary efficacy endpoint ORR, which was measured within 6&nbsp;months
after Kymriah infusion in study B2205J compared to 3&nbsp;months in the pivotal
study. Of 75&nbsp;patients enrolled, 64 received infusion of Kymriah; for 5&nbsp;patients
(6.7%), Kymriah could not be manufactured and 6&nbsp;patients (8.0%) died while
awaiting Kymriah manufacturing in the clinical study. The median duration of
study follow-up defined as the time from Kymriah infusion to the date of completion
or discontinuation from follow-up prior to the data cut-off date in the final
analyses was 12.2&nbsp;months (range: 0.4-49.3). The median time from Kymriah
infusion to the data cut-off date was 31.7&nbsp;months (range: 17.6-56.0).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Among the patients infused, the median age was 12.5&nbsp;years
(range: 3 to 25), 34 (53.1%) were female and 30 (46.9%) were male, 10.9% had
primary refractory disease, 89.1% had relapsed disease, and 43.8% of patients
had at least one prior haematopoietic stem cell <span style='color:black'>transplant.
</span></span><span lang=EN-GB style='color:black'>Baseline disease
characteristics were similar in the enrolled patients with regard to age
(median age 13.0&nbsp;years, range: 3 to 25), gender (46.7% female and 53.3%
male), primary refractoriness (10.7%), and prior transplant history (42.7%).</span><span
lang=EN-GB style='color:black'> The </span><span lang=EN-GB>majority of infused
patients (57/64, 89.1%) received bridging chemotherapy while waiting for
Kymriah. A total of 60 out of 64&nbsp;patients (93.8%) who received Kymriah
infusion also received lymphodepleting chemotherapy after enrolment and prior
to infusion of a single dose of Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Efficacy was established through the primary endpoint of ORR, which
included best overall response as CR or CRi that were maintained for at least
28&nbsp;days within 6&nbsp;months post&#8209;infusion, as determined by IRC
assessment, as well as secondary endpoints including DOR, proportion of
patients who achieved CR or CRi with MRD&#8209;negative disease status, and OS.
Among the patients infused, ORR was demonstrated in 45&nbsp;patients (70.3%; 59.4%
CR and 10.9% CRi). CR/CRi with MRD&#8209;negative bone marrow was reported in 43&nbsp;patients
(67.2%). The median DOR was not reached and the event&#8209;free probability at
12&nbsp;months was 70.5%. The survival probability at 24&nbsp;months was 54.7%,
and the median OS was estimated as 29.9&nbsp;months (95% CI: 15.1, 42.4)<span
style='color:black'>. The OS results were confirmed in an updated OS analyses
(i.e. median OS 29.9&nbsp;months [95% CI: 15.2, NE] with 57.6% survival
probability at 24&nbsp;months; with a median follow&#8209;up for OS of 25.9&nbsp;months),
which included patients transitioned to a separate long&#8209;term follow&#8209;up
study. </span>Seven patients (10.9%) who achieved CR/CRi after Kymriah infusion
proceeded to haematopoietic stem cell transplant while in remission during the
study, of which 5 of the patients (7.8%) proceeded to transplant within the
first 6&nbsp;months post&#8209;infusion.</span><span lang=EN-GB
style='color:black'> Efficacy results reported for the enrolled patients (n=75)
demonstrate an ORR of 60.0% (50.7% CR and 9.3% CRi; 57.3% with MRD&#8209;negative
bone marrow). The reported overall survival in the enrolled population is in accordance
with the infused population.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Special populations</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>No differences in efficacy or safety were observed between different
age subgroups.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Patients with active CNS leukaemia</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Of four patients with active CNS leukaemia (i.e. CNS&#8209;3)
included in study B2101J, three experienced cytokine release syndrome
(Grade&nbsp;2&#8209;4) and transient neurological abnormalities (Grade&nbsp;1&#8209;3)
that resolved within 1&#8209;3&nbsp;months of infusion. One patient died due to
disease progression and the remaining three patients achieved a CR or CRi and
remain alive 1.5&#8209;2&nbsp;years after infusion.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Diffuse large B&#8209;cell lymphoma (DLBCL)</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of Kymriah treatment in adult patients with
relapsed or refractory (r/r) diffuse large B&#8209;cell lymphoma (DLBCL) who
received &#8805;2&nbsp;lines of chemotherapy, including rituximab and
anthracycline, or relapsed following autologous haematopoietic stem cell
transplantation (HSCT), was evaluated in an open&#8209;label, pivotal, single&#8209;arm
study. Patients with T&#8209;cell rich/histiocyte&#8209;rich large B&#8209;cell
lymphoma (THRBCL), primary cutaneous large B&#8209;cell lymphoma, primary
mediastinal B&#8209;cell lymphoma (PMBCL), EBV&#8209;positive DLBCL of the
elderly, Richter’s transformation, and Burkitt lymphoma were not enrolled in
study C2201.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>The pivotal study C2201 (JULIET) is a multicentre,
single&#8209;arm phase II study in adult patients with relapsed or refractory
DLBCL. Of 167&nbsp;patients enrolled, 115&nbsp;patients received infusion with
Kymriah. Approximately 31% of patients discontinued the study prior to Kymriah infusion.
For 13&nbsp;patients (8%) Kymriah could not be manufactured. Other reasons for
discontinuation prior to Kymriah infusion included death (n=16; 10%), physician
decision/primary disease progression (n=16; 10%), patient decision (n=2; 1%),
protocol deviation (n=1; 1%) or adverse events (n=4; 2%) while awaiting Kymriah
manufacturing in the clinical study. </span><span style='font-size:11.0pt'>The
median duration of study follow-up defined as the time from Kymriah infusion to
date of completion or discontinuation from follow-up prior to the data cut-off
date was 7.7&nbsp;months (range: 0.4-35.6). The median time from Kymriah
infusion to the data cut-off date was 26.0&nbsp;months (range: 9.7-38.2). The
study is still ongoing.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>Key baseline information for enrolled and
infused patients is presented in Table&nbsp;5. All patients had leukapheresis
starting material collected and cryopreserved prior to or during study entry.
The majority of patients (103/115, 90%) received bridging therapy for disease
stabilisation. The type and duration of bridging therapy was left to the
discretion of the physician. 107/115&nbsp;patients (93%) received
lymphodepleting chemotherapy prior to Kymriah infusion. Kymriah was given as a
single&#8209;dose (0.6&#8209;6.0&nbsp;x&nbsp;10<sup>8</sup> CAR&#8209;positive
viable T cells) intravenous infusion in a qualified Kymriah treatment centre in
an inpatient and outpatient setting.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-align:left;text-indent:-56.7pt;
page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Table&nbsp;5       Study
C2201: Baseline information across the enrolled and the infused patient
populations</span></b></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-align:left;text-indent:-56.7pt;
page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=606
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:41.05pt'>
   <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
   border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:41.05pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>&nbsp;</b></p>
   </td>
   <td width=156 valign=top style='width:116.85pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:41.05pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Enrolled</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>N=167</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>n
   (%)</b></p>
   </td>
   <td width=156 valign=top style='width:116.85pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:41.05pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Infused</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>N=115</b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>n
   (%)</b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Age
  (years)</b></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Mean
  (standard deviation)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>56
  (12.9)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>54 (13.1)</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Median
  (minimum – maximum)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>58 (22 -
  76)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>56 (22 -
  76)</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Age
  category (years) - n (%)</b></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          &lt;65&nbsp;years</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>120
  (71.9)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>89
  (77.4)</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          &#8805;65&nbsp;years</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>47 (28.1)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>26
  (22.6)</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b>Sex -
  n (%)</b></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Male</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>105
  (62.9)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>71
  (61.7)</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>          Female</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>62 (37.1)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>44
  (38.3)</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Prior haematopoietic stem cell transplant (SCT) - n (%)</span></b></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>          No</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>93 (55.7)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>59 (51.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>          Yes</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>74 (44.3)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>56 (48.7)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Stage III/IV disease at study entry - n (%)</span></b></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>          No</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>36 (21.6)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>27 (23.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>          Yes</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>131 (78.4)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>88 (76.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Number of prior
  lines of antineoplastic therapy – n (%)</span></b></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>          1</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>6 (3.6)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>5 (4.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>          2</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>73 (43.7)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>51 (44.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>          3</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>52 (31.1)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>36 (31.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;text-align:justify;text-justify:inter-ideograph;
  page-break-after:avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>          &#8805;4</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>36 (21.6)</span></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>23 (20.0)</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'><b>Disease status (%)</b></p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>          Refractory to last line
  of therapy</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>98 (58.7)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal;page-break-after:avoid'>63 (54.8)</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal'>          Relapse to last line of therapy</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal'>69 (41.3)</p>
  </td>
  <td width=156 valign=top style='width:116.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
  line-height:normal'>52 (45.2)</p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>The efficacy
of Kymriah was evaluated through the primary endpoint of best overall response
rate (ORR), which includes complete response (CR) and partial response (PR) as
determined by Independent Review Committee (IRC) assessment as well as
secondary endpoints including duration of response (Table&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><a
name="_hd6_Table_4_2_Best_overall27158"></a><a
name="_hd7_Figure_4_1_Kaplan_Meie31722"></a><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><a name="_Toc488242409"><b><span
lang=EN-GB>Table&nbsp;6       </span></b></a><b><span lang=EN-GB>Study C2201:
Efficacy results in adult patients with relapsed or refractory diffuse large B&#8209;cell
lymphoma (DLBCL) after two or more lines of systemic therapy</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=650
 style='width:487.35pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Enrolled patients</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=167</span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Infused patients</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=115</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Primary endpoint<sup>1</sup></span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=147</span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=99</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Overall response
  rate</span></b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>
  <b>(ORR)</b> (CR+PR)<sup>2</sup>, n (%)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>95% CI</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=FR-CH
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>53 (36.1)</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=FR-CH
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(28.3, 44.4)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><b><span lang=FR-CH
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>53 (53.5)</span></b></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=FR-CH
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(43.2, 63.6)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=FR-CH>CR, n (%)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR-CH>40 (27.2)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR-CH>40(40.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=FR-CH>PR, n (%)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR-CH>13 (8.8)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR-CH>13 (13.1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=FR-CH>Response a</span><span lang=EN-GB>t
  month&nbsp;3</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>N=147</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>N=99</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>ORR (%)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>39 (26.5)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>39 (39.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>CR (%)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>34 (23.1)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>34 (34.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Response at month&nbsp;6</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>N=147</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>N=99</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>ORR (%)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>34 (23.1)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>34 (34.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>CR (%)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>31 (21.1)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>31 (31.3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Duration of response (DOR)<sup>3</sup></span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=53</span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=53</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Median (months) (95% CI)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not reached
  (10.0, NE<sup>5</sup>)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not reached
  (10.0, NE<sup>5</sup>)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>% relapse free probability at 12&nbsp;months</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>63.2</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>63.2</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>% relapse free probability at 18&nbsp;months</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>63.2</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>63.2</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Other secondary endpoints</span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=167</span></b></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>N=115</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Overall survival (OS)<sup>4</sup></span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>% survival probability at 12&nbsp;months</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>40.9</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>47.9</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>% survival probability at 24&nbsp;months</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>32.5</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>39.1</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=328 valign=top style='width:246.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB>Median (months) (95% CI)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>8.2 (5.8, 11.7)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>10.3 <span style='color:black'>(6.6, 21.1)</span></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=650 colspan=3 valign=top style='width:487.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1                 </span></sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
  primary endpoint was analysed on all patients whose Kymriah was manufactured
  at the Novartis US facility.</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>2</span></sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>        ORR
  is the proportion of patients with best overall response (BOR) of CR or PR
  based on the Lugano response criteria (Cheson 2014); non&#8209;infused
  patients were assigned BOR=Unknown (i.e. non&#8209;responders).</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>3                 </span></sup><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>DOR
  was defined as time from achievement of CR or PR to relapse or death due to
  DLBCL, whichever occurs first.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  line-height:normal;page-break-after:avoid;text-autospace:none'><sup><span
  lang=EN-GB>4                 </span></sup><span lang=EN-GB>OS was defined as
  time from date of Kymriah infusion to the date of death due to any cause (N=115)
  and time from date of enrolment to the date of death due to any cause for
  enrolled patients (N=167).</span></p>
  <p class=Legend style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid'><sup><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>5</span></sup><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>        Not estimable.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><a
name="_Toc485048491"></a><a name="_Toc488242412"><span lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>Among the 40&nbsp;patients
who achieved CR, 15&nbsp;patients initially had an overall disease response of
PR which improved to CR over time; most patients (13/15) achieved PR to CR
conversion within 6&nbsp;months post-tisagenlecleucel infusion. ORR was consistent
across subgroups.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are not
enough data to determine whether there are any differences in efficacy or
safety between different age subgroups, although the clinical benefit and
safety experience in elderly patients with DLBCL above the age of 65&nbsp;years
(23% of the study population) were comparable to the overall population.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has deferred the obligation to submit the results of studies
with Kymriah</span><span lang=EN-GB style='color:#00B050'> </span><span
lang=EN-GB>in one or more subsets of the paediatric population in the following
conditions: a)&nbsp;treatment of B&#8209;cell lymphoblastic lymphoma, and b)&nbsp;treatment
of mature B&#8209;cell neoplasms (see section&nbsp;4.2 for information on
paediatric use).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2     Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Following infusion of Kymriah into paediatric and young adult r/r B&#8209;cell
ALL and r/r DLBCL patients, tisagenlecleucel typically exhibited an initial
rapid expansion followed by a slower bi&#8209;exponential decline.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Cellular kinetics in paediatric and young adult B&#8209;cell ALL
patients</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>A summary of cellular kinetic parameters of tisagenlecleucel in
paediatric and young adult B&#8209;cell ALL patients is provided in Table&nbsp;7
below. The maximal expansion (C<sub>max</sub>) was approximately 1.6&#8209;fold
higher in CR/CRi patients (n=103) compared with non&#8209;responding (NR)
patients (n=10) as measured by qPCR. Delayed and lower expansion was observed
in NR patients compared to CR/CRi patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<h6 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:56.7pt;
text-indent:-56.7pt'><a name="_Toc491696953"><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Table&nbsp;7       Cellular kinetic parameters of
tisagenlecleucel in paediatric and young adult r/r B&#8209;cell ALL</span></a><span
lang=EN-GB style='font-family:"Times New Roman",serif'> (Studies B2202 and
B2205J)</span></h6>

<p class=Text style='margin-top:0in;page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=159 valign=top style='width:119.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Parameter</span></p>
  </td>
  <td width=150 valign=top style='width:112.3pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Summary statistics</span></p>
  </td>
  <td width=154 valign=top style='width:115.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Responding patients (CR/CRi)</span></p>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>N=105</span></p>
  </td>
  <td width=156 valign=top style='width:116.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Non&#8209;responding patients (NR)</span></p>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;color:black'>N</span><span lang=EN-GB
  style='font-size:11.0pt'>=12</span></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>C<sub>max</sub> (copies/</span><span
  class=st1><span lang=EN-GB style='font-size:11.0pt;color:#545454'>&#956;</span></span><span
  lang=EN-GB style='font-size:11.0pt'>g)</span></p>
  </td>
  <td width=150 valign=top style='width:112.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Geometric mean (CV%), n</span></p>
  </td>
  <td width=154 valign=top style='width:115.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>35,300 (154.0), 103</span></p>
  </td>
  <td width=156 valign=top style='width:116.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>21,900 (80.7), 10</span></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>T<sub>max</sub><sup>‡</sup> (day)</span></p>
  </td>
  <td width=150 valign=top style='width:112.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median [min;max], n</span></p>
  </td>
  <td width=154 valign=top style='width:115.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>9.83 [5.70; 27.8], 103</span></p>
  </td>
  <td width=156 valign=top style='width:116.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>20.1 [12.6; 62.7], 10</span></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>AUC<sub>0&#8209;28d </sub>(copies/</span><span
  class=st1><span lang=EN-GB style='font-size:11.0pt;color:#545454'>&#956;</span></span><span
  lang=EN-GB style='font-size:11.0pt'>g*day)</span></p>
  </td>
  <td width=150 valign=top style='width:112.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Geometric mean (CV%), n</span></p>
  </td>
  <td width=154 valign=top style='width:115.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>309,000 (178.1), 103</span></p>
  </td>
  <td width=156 valign=top style='width:116.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>232,000 (104.5), 8</span></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>T<sub>½</sub> (day)</span></p>
  </td>
  <td width=150 valign=top style='width:112.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Geometric mean (CV%), n</span></p>
  </td>
  <td width=154 valign=top style='width:115.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>25.2 (307.8), 71</span></p>
  </td>
  <td width=156 valign=top style='width:116.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>3.80 (182.4), 4</span></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>T<sub>last</sub></span></p>
  </td>
  <td width=150 valign=top style='width:112.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median [min;max], n</span></p>
  </td>
  <td width=154 valign=top style='width:115.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>166 [20.9; 916], 103</span></p>
  </td>
  <td width=156 valign=top style='width:116.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>28.8 [26.7; 742], 9</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=4 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Cellular kinetics in adult DLBCL patients</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A summary of
cellular kinetic parameters of tisagenlecleucel in DLBCL patients is provided
in Table&nbsp;8 below.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h6 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:56.7pt;
text-indent:-56.7pt'><a name="_Toc491696954"><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Table&nbsp;8       Cellular kinetic parameters of tisagenlecleucel
in r/r DLBCL patients</span></a></h6>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=157 valign=top style='width:118.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Parameter</span></p>
  </td>
  <td width=147 valign=top style='width:110.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Summary statistics</span></p>
  </td>
  <td width=152 valign=top style='width:113.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Responding patients</span></p>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>(CR and PR)</span></p>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>N=43</span></p>
  </td>
  <td width=163 valign=top style='width:122.2pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Non&#8209;responding patients</span></p>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>(SD/PD/Unknown)</span></p>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>N=72</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:118.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>C<sub>max</sub> (copies/</span><span
  class=st1><span lang=EN-GB style='font-size:11.0pt;color:#545454'>&#956;</span></span><span
  lang=EN-GB style='font-size:11.0pt'>g)</span></p>
  </td>
  <td width=147 valign=top style='width:110.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Geometric mean (CV%), n</span></p>
  </td>
  <td width=152 valign=top style='width:113.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>5,840 (254.3), 43</span></p>
  </td>
  <td width=163 valign=top style='width:122.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>5,460 (326.89), 65</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:118.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>T<sub>max</sub> (day)</span></p>
  </td>
  <td width=147 valign=top style='width:110.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median [min;max], n</span></p>
  </td>
  <td width=152 valign=top style='width:113.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>9.00 [5.78; 19.8], 35</span></p>
  </td>
  <td width=163 valign=top style='width:122.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>8.84 [3.04; 27.7], 65</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:118.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>AUC<sub>0&#8209;28d </sub>(copies/</span><span
  class=st1><span lang=EN-GB style='font-size:11.0pt;color:#545454'>&#956;</span></span><span
  lang=EN-GB style='font-size:11.0pt'>g*day)</span></p>
  </td>
  <td width=147 valign=top style='width:110.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Geometric mean (CV%), n</span></p>
  </td>
  <td width=152 valign=top style='width:113.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>61,200 (177.7), 40</span></p>
  </td>
  <td width=163 valign=top style='width:122.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>67,000 (275.2), 56</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:118.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>T<sub>½</sub> (day)</span></p>
  </td>
  <td width=147 valign=top style='width:110.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Geometric mean (CV%), n</span></p>
  </td>
  <td width=152 valign=top style='width:113.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>129 (199.2), 33</span></p>
  </td>
  <td width=163 valign=top style='width:122.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>14.7 (147.1), 44</span></p>
  </td>
 </tr>
 <tr>
  <td width=157 valign=top style='width:118.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>T<sub>last</sub></span></p>
  </td>
  <td width=147 valign=top style='width:110.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>Median [min;max], n</span></p>
  </td>
  <td width=152 valign=top style='width:113.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>551 [17.1; 1030], 43</span></p>
  </td>
  <td width=163 valign=top style='width:122.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt'>61.4 [19.8; 685], 56</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Dis<span
lang=EN-GB>tribution</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In paediatric and young adult B&#8209;cell ALL patients, tisagenlecleucel
has been shown to be present in the blood and bone marrow beyond 2&nbsp;years. The
blood to bone marrow partitioning of tisagenlecleucel in bone marrow was 47.2% of
that present in blood at day&nbsp;28 while at months&nbsp;3 and 6 it distributes
at 68.3% and 69%, respectively (</span><span lang=EN-GB>Studies&nbsp;B2202 and
B2205J)</span><span lang=EN-GB>. </span><span lang=EN-GB>T</span><span
lang=EN-GB>isagenlecleucel also traffics and persists in cerebrospinal fluid in
paediatric and young adult B&#8209;cell ALL patients (Study B2101J) for up to
1&nbsp;year.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In adult DLBCL patients (Study C2201), tisagenlecleucel has been
detected for up to 3&nbsp;years in peripheral blood and up to month&nbsp;9 in
bone marrow for complete responder patients. The blood to bone marrow
partitioning in bone marrow was nearly 70% of that present in blood at day&nbsp;28
and 50% at month&nbsp;3 in both responder and non&#8209;responder patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The elimination profile of Kymriah includes a bi&#8209;exponential
decline in peripheral blood and bone marrow.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Linearity/non&#8209;linearity</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is no apparent relationship between dose and AUC<sub>0&#8209;28d</sub>
or C<sub>max</sub>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Elderly</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The scatter
plots of cellular kinetic parameters versus age (22&#8209;76&nbsp;years)
revealed no relevant relationship between cellular kinetic parameters (AUC<sub>0&#8209;28d</sub>
and C<sub>max</sub>) with age.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Gender</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Gender is not a significant characteristic influencing tisagenlecleucel
expansion in B&#8209;cell ALL and DLBCL patients. In Study B2202, there were 43%
female and 57% male patients and in Study C2201 38% female and 62% male
patients who received Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Race/ethnicity</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is limited
evidence that race/ethnicity impact the expansion of Kymriah in paediatric and
young adult ALL and DLBCL patients. In Study B2202 there were 73.4% Caucasian, 12.7%
Asian and 13.9% other ethnic patients. In Study C2201 there were 85% Caucasian,
9% Asian, 4% Black or African American patients, and 3&nbsp;patients (3%) of
unknown race.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Body weight</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In ALL and DLBCL patients, across the weight ranges (ALL; 14.4 to
137&nbsp;kg; DLBCL: 38.4 to 186.7&nbsp;kg), the scatter plots of qPCR cellular
kinetic parameters versus weight revealed no apparent relationship between
cellular kinetic parameters with weight.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Prior transplantation</span></u></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Prior transplantation did not impact the expansion/persistence of Kymriah
in paediatric and young adult B&#8209;Cell ALL patients or DLBCL patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3     Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Non&#8209;clinical
safety assessment of Kymriah addressed the safety concerns of potential
uncontrolled cell growth of transduced T cells <i>in vitro</i> and <i>in vivo</i>
as well as dose&#8209;related toxicity, biodistribution and persistence. No
such risks were identified based on these studies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Carcinogenicity and mutagenicity</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Genotoxicity
assays and carcinogenicity studies in rodents are not appropriate to assess the
risk of insertional mutagenesis for genetically&#8209;modified cell therapy
products. No alternative adequate animal models are available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> expansion studies with CAR&#8209;positive T cells (Kymriah) from
healthy donors and patients showed no evidence for transformation and/or
immortalisation of T cells. <i>In vivo</i> studies in immunocompromised mice
did not show signs of abnormal cell growth or signs of clonal cell expansion
for up to 7&nbsp;months, which represents the longest meaningful observation
period for immunocompromised mouse models. A genomic insertion site analysis of
the lentiviral vector was performed on Kymriah products from 14&nbsp;individual
donors (12&nbsp;patients and 2&nbsp;healthy volunteers). There was no evidence
for preferential </span><span lang=EN-GB>integration near genes of concern or
preferential outgrowth of cells harbouring integration sites of concern</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Reproductive toxicity</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No non&#8209;clinical
reproductive safety studies were conducted as no adequate animal model is
available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Juvenile animal studies</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Juvenile
toxicity studies were not conducted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.       PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Glucose</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Human albumin
solution</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dextran 40 for
injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dimethylsulfoxide</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium gluconate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium acetate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Potassium
chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Magnesium
chloride</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium&#8209;N&#8209;acetyltryptophanate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sodium caprylate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Aluminium</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the absence
of compatibility studies, this medicinal product must not be mixed with other
medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>9&nbsp;months.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The product
should be administered immediately after thawing. After thawing, the product
should be kept at room temperature (20°C&#8209;25°C) and infused within 30&nbsp;minutes
to maintain maximum product viability, including any interruption during the infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store and
transport below &#8209;120°C, e.g. in a container for cryogenic storage (Dewar)
in the vapour phase of liquid nitrogen.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original protective envelope (Tyvek) containing the cassette protecting the infusion
bag.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after thawing of the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5     Nature and contents
of container and special equipment for use, administration or implantation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ethylene vinyl
acetate (EVA) infusion bag with polyvinyl chloride (PVC) tubing and a luer
spike interconnector closed by a luer&#8209;lock cap containing either
10–30&nbsp;mL (50&nbsp;mL bags) or 30–50&nbsp;mL (250&nbsp;mL bags) cell
dispersion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Each infusion bag is placed into
an aluminum cassette, then put in a plastic overwrap bag with absorbent sheets
and sealed in a protective envelope (Tyvek).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>One individual treatment dose comprises
1 or more infusion bags.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6     Special
precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Inspection and thawing of the infusion bag(s)</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not thaw the
product until it is ready to be used.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The infusion bag
should be placed inside a second sterile bag during thawing to protect ports
from contamination and avoid spills in the unlikely event of the bag leaking. </span><span
lang=EN-GB>Kymriah should be thawed at 37°C using either a water bath or dry
thaw method until there is no visible ice in the infusion bag. The bag should
be removed immediately from the thawing device and kept at room temperature (20°C&#8209;25°C)
until infusion. If more than one infusion bag has been received for the
treatment dose, the next bag should only be thawed after the contents of the preceding
bag have been infused.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah should <u>not</u>
be manipulated. For example, Kymriah should not be washed (spun down and
resuspended in new media) prior to infusion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The infusion bag(s)
should be examined for any breaks or cracks prior to thawing. If the infusion bag
appears to have been damaged or to be leaking, it should not be infused and
should be disposed of according to local procedures on handling of biological
waste (see section&nbsp;4.2.).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeader style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Precautions
to be taken for transport and disposal of the medicinal product</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah should
be transported within the facility in closed, break&#8209;proof, leak&#8209;proof
containers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah contains
genetically&#8209;modified human blood cells. Local guidelines on handling of
biological waste should be followed for unused medicinal product or waste
material. All material that has been in contact with Kymriah (solid and liquid
waste) should be handled and disposed in accordance with local guidelines on
handling of biological waste.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.       MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.       MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/18/1297/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.       DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>23 August 2018</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
line-height:normal'><b><span lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.      MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE
AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>D.      <span style='text-transform:uppercase'>conditions
or restrictions with regard to the safe and effective use of the medicinal
product</span></span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.      MANUFACTURERS OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturers of the biological active substance</span></u></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Fraunhofer
Institut für Zelltherapie und Immunologie</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Perlickstrasse 1</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Hauptgebäude und
Erweiterungsbau 1</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>D-04103 Leipzig</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
Pharmaceutical Corporation</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>220 East Hanover
Avenue</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Morris Plains</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>New Jersey</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NJ07950</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>United States</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis Pharma
Stein AG</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis Technical
Operations Schweiz</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Stein Cell and
Gene Therapy,</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Schaffhauserstrasse</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>4332 Stein</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Switzerland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>CELLFORCURE</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>ZA de Courtabœuf</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>11 avenue des
Tropiques</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>91940 Les Ulis</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>France</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis Pharma
GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Roonstrasse 25</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>D-90429
Nuremberg</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>CELLFORCURE</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>ZA de Courtabœuf</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>11 avenue des
Tropiques</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>91940 Les Ulis</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>France</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The printed
package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="OLE_LINK2"><b><span lang=EN-GB>B.</span></b></a><b><span
lang=EN-GB>      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex I: Summary of
Product Characteristics, section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The requirements for submission of </span><span lang=EN-GB>PSURs</span><span
lang=EN-GB> for this medicinal product are set out in the list of Union
reference dates (EURD list) </span><span lang=EN-GB>provided for under Article
107c(7) of Directive 2001/83</span><span lang=EN-GB>/EC</span><span lang=EN-GB>
and </span><span lang=EN-GB>any subsequent updates published on the European
medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The marketing
authorisation holder (MAH) shall submit the first PSUR for this product within
6&nbsp;months following authorisation.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>D.      CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The marketing authorisation holder (MAH) shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the marketing authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Key elements:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Availability of tocilizumab and site qualification</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>To minimise the risks associated with KYMRIAH treatment, the MAH
must ensure that hospitals and their associated centres that dispense KYMRIAH
are specially qualified in accordance with the agreed control distribution
programme.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>The MAH must ensure on&#8209;site, immediate access to tocilizumab
for each patient as CRS management medication prior to treating patients. </span><span
lang=EN-GB>Hospitals should have access to additional doses of tocilizumab
within 8&nbsp;hours.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>KYMRIAH will only be supplied to hospitals and associated centres that
are qualified and only if the healthcare professionals involved in the
treatment of a patient have completed the educational programme.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Educational programme</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Prior to the launch of KYMRIAH in each Member State, the MAH must
agree about the content and format of the educational materials with the
National Competent Authority.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>HCP educational programme</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The MAH shall ensure that in each Member State where KYMRIAH is
marketed, all HCPs who are expected to prescribe, dispense annd administer
KYMRIAH shall be provided with a guidance document to:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facilitate identification of CRS and serious
neurological adverse reactions</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facilitate management of the CRS and serious
neurological adverse reactions</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ensure adequate monitoring of CRS and serious
neurological adverse reactions</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>facilitate provision of all relevant information
to patients</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ensure that adverse reactions are adequately and
appropriately reported</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ensure that detailed instructions about the
thawing procedure are provided</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>before treating a patient, ensure that
tocilizumab for each patient are available on site</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Patient educational programme</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>To inform and explain to patients:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the risks of CRS and serious neurological
adverse reactions associated with KYMRIAH</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the need to report the symptoms to their
treating doctor immediately</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the need to remain in the proximity of the
location where KYMRIAH was received for at least 4&nbsp;weeks following KYMRIAH
infusion</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>the need to carry the patient alert card at all
times</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Obligation to conduct post&#8209;authorisation
measures</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The MAH shall complete, within the stated timeframe,
the below measures:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width="69%" valign=top style='width:69.6%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Description</span></b></p>
  </td>
  <td width="30%" valign=top style='width:30.4%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Due date</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="69%" valign=top style='width:69.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Non&#8209;interventional post&#8209;authorisation
  safety study (PASS): In order to further characterise the safety – including
  long&#8209;term safety – of Kymriah, the applicant should conduct and submit
  a study based on data from a disease registry in ALL and DLBCL patients.</span></p>
  </td>
  <td width="30%" valign=top style='width:30.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Update reports:</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Annual safety reports and 5&#8209;yearly interim
  reports</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Final report of study results:</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>December 2038</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="69%" valign=top style='width:69.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Post&#8209;authorisation efficacy study (PAES): In
  order to further evaluate the efficacy and safety of Kymriah in ALL patients
  below the age of 3&nbsp;years, the applicant should conduct and submit a
  study based on data from a disease registry in ALL patients.</span></p>
  </td>
  <td width="30%" valign=top style='width:30.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Update reports:</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Included as part of the annual reports of the non&#8209;interventional
  PASS</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Final report: December 2023</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="69%" valign=top style='width:69.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Post&#8209;authorisation efficacy study (PAES): In order to
  further evaluate the efficacy of Kymriah in patients with relapsed/refractory
  DLBCL, the applicant should conduct and submit a prospective, observational
  study in patients with r/r DLBCL based on data from registry with efficacy
  outcome measures in line with study C2201, including details of the
  manufacturing turnaround time (i.e. time from last relapse or confirmed
  refractory status, time from decision to treat, and time from leukapheresis
  to infusion).</span></p>
  </td>
  <td width="30%" valign=top style='width:30.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>June 2022</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="69%" valign=top style='width:69.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Post&#8209;authorisation efficacy study (PAES): In order to
  further characterise the long&#8209;term efficacy and safety of Kymriah in
  relapsed/refractory DLBCL, the applicant should submit the 24&nbsp;months
  follow&#8209;up of all infused patients from study C2201. In addition the
  applicant should submit the final CSR including 5&nbsp;years of follow&#8209;up.</span></p>
  </td>
  <td width="30%" valign=top style='width:30.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Updated report:</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>November 2020</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Final CSR: August 2023</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="69%" valign=top style='width:69.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Post&#8209;authorisation efficacy study (PAES): In order to
  further characterise the long&#8209;term efficacy and safety of Kymriah in
  relapsed/refractory DLBCL, the applicant should submit the results of study
  CCTL019H2301 – open&#8209;label, Phase III study of Kymriah versus standard
  of care in adult patients with relapsed or refractory aggressive B&#8209;cell
  non&#8209;Hodgkin lymphoma.</span></p>
  </td>
  <td width="30%" valign=top style='width:30.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>June 2022</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INFUSION BAG LABEL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Kymriah 1.</span><span
lang=FR-CH>2&nbsp;x&nbsp;10<sup>6</sup>&nbsp;–&nbsp;6&nbsp;x&nbsp;10<sup>8</sup>
cells</span><span lang=FR-CH> dispersion for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>tisagenlecleucel
(CAR+ viable T cells)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Autologous human
T cells genetically modified <i>ex vivo</i> using a lentiviral vector encoding
an anti&#8209;CD19 chimeric antigen receptor (CAR).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Contains 1.2&nbsp;x&nbsp;10<sup>6</sup>
to 6&nbsp;x&nbsp;10<sup>8</sup> CAR+ viable T cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Also contains:
glucose, sodium chloride, human albumin solution, dextran 40 for injection,
dimethylsulfoxide, sodium gluconate, sodium acetate, potassium chloride,
magnesium chloride, sodium&#8209;N&#8209;acetyltryptophanate, sodium caprylate,
aluminium, water for injections. <span style='color:black;background:#D9D9D9'>See
leaflet for further information.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Dispersion for infusion</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>10&nbsp;mL&nbsp;&#8209;&nbsp;50&nbsp;mL
per bag.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use
leukocyte depleting filter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For autologous
use only.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Store and transport below &#8209;120°C; do not thaw the product
until use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Contains genetically&#8209;modified
cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dispose of as
per local guideline on handling of biological waste.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;background:#D9D9D9'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='color:black;background:#D9D9D9'>Vista Building</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='color:black;background:#D9D9D9'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='color:black;background:#D9D9D9'>Dublin 4</span></p>

<p class=MsoNormal style='line-height:normal'><span style='color:black;
background:#D9D9D9'>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/18/1297/001</span></p>
  </td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black;background:#D9D9D9'>10 – 50&nbsp;ml</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER,
DONATION AND PRODUCT CODES</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Name:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of birth: <span
style='color:black;background:#D9D9D9'>{DD MMM YYYY}</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Aph ID/DIN:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Batch:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bag <span
style='color:black;background:#D9D9D9'>x</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE
IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Not applicable</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER &#8209; HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:#D9D9D9'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Not applicable</span><span lang=EN-GB><br
clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient or carer</span></b></p>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=FR-CH>Kymriah 1.</span></b><b><span lang=FR-CH>2&nbsp;x&nbsp;10<sup>6</sup>&nbsp;–&nbsp;6&nbsp;x&nbsp;10<sup>8</sup>
cells</span></b><b><span lang=FR-CH> dispersion for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=FR-CH>tisagenlecleucel (CAR+ viable T cells)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB><img border=0
width=21 height=18 id="Picture 1"
src="Kymriah%20II-30%20-%20EN%20PI%20clean_files/image002.gif"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicine is subject to
additional monitoring. This will allow quick identification of new safety
information. You can help by reporting any side effects you may get. See the
end of section&nbsp;4 for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you (or your child) are given this medicine
because it contains important information.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor.</span><span lang=EN-GB style='color:red'> </span><span lang=EN-GB>This
includes any possible side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will give you a Patient Alert Card.
Read it carefully and follow the instructions on it.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Always show the Patient Alert Card to the doctor
or nurse when you see them or if you go to hospital.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The information in this leaflet is for you or
your child – but in the leaflet it will just say “you”.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.       What Kymriah is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.       What you need to know before you are given Kymriah</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.       How Kymriah is given</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.       How to store Kymriah</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.       What Kymriah is and
what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>Kymriah is</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah, also
known as tisagenlecleucel, is made from some of your own white blood</span><span
lang=EN-GB> cells</span> called T cells. T cells <span lang=EN-GB>are important
for your immune system (the body’s defences) to work properly.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>How does Kymriah work?</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The T cells are
taken</span><span lang=EN-GB> from your blood and a new gene is put into the T
cells so that they can target the cancer cells in your body. When Kymriah is
infused into your blood, the modified T cells will find and kill the cancer cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Kymriah is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kymriah is used to treat:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>B&#8209;cell acute lymphoblastic leukaemia (B&#8209;cell
ALL)</span></b><span lang=EN-GB> &#8209; a form of cancer that affects some other
types of white blood cells. The medicine can be used in children and young
adults up to and including 25&nbsp;years of age with this cancer.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diffuse</span></b><b><span lang=EN-GB> large
B&#8209;cell lymphoma (DLBCL)</span></b><span lang=EN-GB> &#8209;</span><span
lang=EN-GB> another form of cancer that affects some types of white blood
cells, mostly in the lymph nodes. The medicine can be used in adults
(18&nbsp;years of age or older) with this cancer.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
questions about how Kymriah works or why this medicine has been prescribed for
you, ask your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.       What you need to
know before you are given Kymriah</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>You should not be given Kymriah:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to any of the ingredients of
this medicine (listed in section&nbsp;6).</span><span lang=EN-GB> If you think
you may be allergic, ask your doctor for advice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah is made
from your own white blood cells and should only be given to you.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Before you are given Kymriah you should tell your doctor if:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You have had a stem cell transplant in the last 4&nbsp;months.
Your doctor will check if you have signs or symptoms of graft&#8209;versus&#8209;host
disease. This happens when transplanted cells attack your body, causing
symptoms such as rash, nausea, vomiting, diarrhoea and bloody stools.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You have any lung, heart or blood pressure (low
or raised) problems.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You notice the symptoms of your cancer are
getting worse. If you have leukaemia this might include fever, feeling weak,
bleeding gums, bruising. If you have lymphoma, this might include unexplained
fever, feeling weak, night sweats, sudden weight loss.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You have an infection. The infection will be
treated before the Kymriah infusion.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You have had hepatitis B, hepatitis C or human
immunodeficiency virus (HIV) infection.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You are pregnant, think you may be pregnant, or
plan to become pregnant (see sections “Pregnancy and breast&#8209;feeding” and “Contraception
for women and men” below).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You had a vaccination in the previous
6&nbsp;weeks or are planning to have one in the next few months.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If any of the
above apply to you (or you are not sure), talk to your doctor before being
given Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Test and checks</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Before you are given Kymriah</span></b><span lang=EN-GB> <b>your
doctor will:</b></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Check your lungs, heart and blood pressure.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Look for signs of infection; any infection will
be treated before you are given Kymriah.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Check if your lymphoma or leukaemia is getting
worse.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Look for signs of graft&#8209;versus&#8209;host disease
that can happen after a transplant.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><s><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></s><span lang=EN-GB>Check your blood for uric acid and for how
many cancer cells there are in your blood. This will show if you are likely to
develop a condition called tumour lysis syndrome. You may be given medicines to
help prevent the condition.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Check for hepatitis B, hepatitis C or HIV infection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>After you have been given Kymriah</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Tell your doctor or nurse immediately if you have any of the
following:</span></b></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever, which may be a symptom of an infection.
Your doctor will regularly check your blood counts as the number of blood cells
and other blood components may decrease.</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take your temperature twice a day for 3&#8209;4&nbsp;weeks
after treatment with Kymriah. If your temperature is high, see your doctor
immediately.</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Extreme tiredness, weakness and shortness of
breath, which may be symptoms of a lack of red blood cells.</span></p>

<p class=MsoNormal style='margin-left:28.4pt;text-indent:-28.4pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bleeding or bruising more easily, which may be
symptoms of low levels of cells in the blood known as platelets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There may be an
effect on the results of some types of HIV test – ask your doctor about this.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor will
regularly monitor your blood counts after you receive Kymriah as you may
experience a reduction in the number of blood cells and other blood components.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not donate
blood, organs, tissues or cells.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>No formal studies have been performed in paediatric
patients below 3&nbsp;years of age in B&#8209;cell ALL.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kymriah should not be used in children and adolescents
below 18&nbsp;years of age to treat DLBCL</span><span lang=EN-GB>. This is
because Kymriah has</span><span lang=EN-GB> not been studied in this age group.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Kymriah</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor if you are taking, have recently taken or might
take any other medicines, including medicines obtained without a prescription.
This is because other medicines can affect the way Kymriah works.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In particular, you must not be given certain vaccines called live
vaccines:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>in the 6&nbsp;weeks before you are given the
short course of chemotherapy (called lymphodepleting chemotherapy) to prepare
your body for the Kymriah cells.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>during Kymriah treatment.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>after treatment while the immune system is
recovering.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor if you need to have any vaccinations.</span></p>

<p class=MsoNormal style='margin-right:1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:1.4pt;line-height:normal'><span
lang=EN-GB>Before<span style='letter-spacing:-.3pt'> </span><span
style='letter-spacing:.05pt'>y</span>ou<span style='letter-spacing:-.3pt'> </span>are<span
style='letter-spacing:-.3pt'> </span>given<span style='letter-spacing:-.25pt'> </span>Kymriah<span
style='letter-spacing:-.3pt'> </span>tell<span style='letter-spacing:-.2pt'> </span>your<span
style='letter-spacing:-.25pt'> </span>doctor<span style='letter-spacing:-.25pt'>
</span>or<span style='letter-spacing:-.3pt'> </span>nurse<span
style='letter-spacing:-.3pt'> </span>if<span style='letter-spacing:-.3pt'> </span><span
style='letter-spacing:.05pt'>y</span>ou<span style='letter-spacing:-.25pt'> </span>are<span
style='letter-spacing:-.3pt'> </span>taking<span style='letter-spacing:-.25pt'>
</span>any<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:
-.1pt'>m</span>edicines<span style='letter-spacing:-.25pt'> </span><span
style='letter-spacing:.05pt'>t</span>hat we<span style='letter-spacing:-.05pt'>a</span>ken<span
style='letter-spacing:-.35pt'> </span><span style='letter-spacing:.05pt'>y</span>our
<span style='letter-spacing:.05pt'>i</span>m<span style='letter-spacing:-.15pt'>m</span>une<span
style='letter-spacing:-.35pt'> </span>s<span style='letter-spacing:.05pt'>y</span>stem<span
style='letter-spacing:-.35pt'> </span>such<span style='letter-spacing:-.3pt'> </span>as<span
style='letter-spacing:-.35pt'> </span>co<span style='letter-spacing:.05pt'>r</span>ticosteroids,<span
style='letter-spacing:-.35pt'> </span>since<span style='letter-spacing:-.35pt'>
</span>these<span style='letter-spacing:-.3pt'> </span>medicines<span
style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.1pt'>m</span>ay<span
style='letter-spacing:-.3pt'> </span>interfere<span style='letter-spacing:-.35pt'>
</span>with<span style='letter-spacing:-.3pt'> </span>the effe<span
style='letter-spacing:-.05pt'>c</span>t<span style='letter-spacing:-.55pt'> </span>of<span
style='letter-spacing:-.5pt'> </span>Kymriah.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy and breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you are pregnant or breast&#8209;feeding, think you may be
pregnant or are planning to have a baby, ask your doctor for advice before being
given this medicine. This is because the effects of Kymriah in pregnant or
breast&#8209;feeding women are not known, and it may harm your unborn baby or
your newborn/infant.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If</span><span lang=EN-GB> you become pregnant
or think you may be pregnant after treatment with Kymriah, talk your doctor
immediately.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You will be given a pregnancy test before
treatment starts. Kymriah should only be given if the result shows you are not
pregnant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Contraception for women and men</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discuss
pregnancy with your doctor if you have received Kymriah.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not drive, use machines, or take part in activities that need you
to be alert for. Kymriah can cause problems such as altered or decreased
consciousness, confusion and seizures (fits) in the 8&nbsp;weeks following
infusion.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Kymriah contains sodium, dimethylsulfoxide (DMSO) and dextran 40.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains 24.3 to 121.5&nbsp;mg sodium per dose. This
is equivalent to 1 to 6% of the recommended maximum daily dietary intake of 2&nbsp;g
sodium for an adult. If you have not been previously exposed to dextran or DMSO
you should be observed closely during the first minutes of the infusion period.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.       How Kymriah is
given</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Kymriah will always be given to you by a doctor in a
qualified treatment centre.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah contains
human blood cells. Your doctor handling Kymriah will therefore take appropriate
precautions (wearing gloves and glasses) to avoid potential transmission of
infectious diseases.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Giving blood to make Kymriah</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kymriah is made from your own white blood cells.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will take some of your blood using a
catheter placed in your vein (a procedure called leukapheresis). Some of your
white blood cells are separated from your blood and the rest of your blood is
returned to your vein. This can take 3 to 6&nbsp;hours and may need to be
repeated.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your white blood cells are frozen and sent away
to make Kymriah. It usually takes about 3 to 4&nbsp;weeks to make Kymriah but
the time may vary.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kymriah is a treatment that is manufactured
specifically for you. There are situations where Kymriah cannot be successfully
manufactured and be given to you. In some cases, a second manufacturing of
Kymriah may be attempted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Before you are
given Kymriah, your doctor may give you a type of treatment called
lymphodepleting chemotherapy for a few days to prepare your body.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><b><span style='font-size:11.0pt'>Cancer treatment while Kymriah is
being made</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>During the period while Kymriah is being made, your </span><span
lang=EN-GB>lymphoma or leukaemia may get worse and your doctor may decide to
use an additional treatment (a type of chemotherapy known as “bridging
therapy”) to stabilise your cancer </span><span lang=EN-GB>by stopping new
cancer cells from developing</span><span lang=EN-GB>. This t</span><span
lang=EN-GB>reatment </span><span lang=EN-GB>may lead to side effects and these
may be severe or life-threatening. Your doctor will inform you of the potential
side effects of this treatment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Medicines given immediately before Kymriah treatment</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>During the 30 to 60&nbsp;minutes before you are given Kymriah you
may be given other medicines. This is to help prevent infusion reactions and
fever. These other medicines may include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Paracetamol</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>An antihistamine such as diphenhydramine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>How you are given Kymriah</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will check that the individual
patient identifiers on the Kymriah infusion bag match up to you.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will give you Kymriah by infusion,
which means it will be given as a drip through a tube in your vein. This
usually takes less than 1&nbsp;hour.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kymriah is a one&#8209;time treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>After you are given Kymriah</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Plan to stay within 2&nbsp;hours’ travel from
the hospital where you were treated for at least 4&nbsp;weeks after you have
been given Kymriah. Your doctor will recommend that you return to the hospital daily
for at least 10&nbsp;days and will consider whether you need to stay at the hospital
as an in&#8209;patient for the first 10&nbsp;days after infusion. This is so
your doctor can check if your treatment is working and help you if you have any
side effects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you miss an appointment, call your doctor or the hospital as soon
as possible to reschedule.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.       Possible side
effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Like all medicines, this medicine can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Tell your doctor immediately</span></b><span lang=EN-GB> if you get
any of the following side effects after the Kymriah infusion. They usually
happen in the first 8&nbsp;weeks after the infusion, but can also develop later:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common: may affect more than 1 in 10&nbsp;people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high fever and chills. These may be symptoms of
a serious condition called cytokine release syndrome which </span><span
lang=EN-GB>may be life-threatening or fatal</span><span lang=EN-GB>. Other
symptoms of cytokine release syndrome are difficulty breathing, nausea,
vomiting, diarrhoea, loss of appetite, fatigue, muscle pain, joint pain, swelling,
low blood pressure, headache, heart, lung and kidney failure and liver injury.
These symptoms almost always occur </span><span lang=EN-GB>within the first
10&nbsp;days after infusion.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>problems such as altered thinking or decreased
consciousness, loss of contact with reality, confusion, agitation, seizures,
difficulty speaking and understanding speech, difficulty walking.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling warm, fever, chills or shivering, sore
throat or mouth ulcers may be signs of an infection. </span><span lang=EN-GB>Some
infections may be life-threatening or fatal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common: may affect up to 1 in 10&nbsp;people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rapid breakdown of tumour cells causing release
of their contents into the bloodstream. This can interfere with the workings of
various body organs, especially the kidneys, heart and nervous system</span><span
lang=EN-GB> </span>(tumour lysis syndrome).</p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Other possible side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Other side effects are listed below. If these side
effects become severe or serious, tell your doctor immediately.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common:</span></b><span lang=EN-GB> <i>may affect more than 1
in 10&nbsp;people</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pale skin, weakness, breathlessness due to low
number of red blood cells or low haemoglobin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Excessive or prolonged bleeding or bruising due
to l</span><span lang=EN-GB style='color:black;background:white'>ow number of
platelets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black;background:white'>Fever with dangerously
low white blood cell count</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black;background:white'>Increased
risk of infection due to abnormally low number of white blood cells</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='letter-spacing:-.05pt'>Frequent</span><span
lang=EN-GB style='letter-spacing:.3pt'> </span><span lang=EN-GB>and<span
style='letter-spacing:1.35pt'> </span><span style='letter-spacing:-.05pt'>persistent
infections due to decreased</span><span style='letter-spacing:.3pt'> </span>antibodies
in<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.1pt'>your</span><span
style='letter-spacing:.4pt'> </span>blood</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Weakness, abnormal heart rhythms, muscle
spasms/cramping due to abnormal low level of blood salts including </span><span
lang=EN-GB>phosphorus</span><span lang=EN-GB>, calcium, potassium, magnesium</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>High levels of liver enzymes or creatinine in
the blood that show that your liver or kidneys are not working normally</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Anxiety, irritability</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fast or irregular heart beat</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Raised blood pressure</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shortness of breath, laboured breathing, rapid
breathing, fluid in the lungs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cough</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abdominal pain, constipation</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin rash</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Difficulty sleeping</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swollen ankles, limbs and face</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common:</span></b><span lang=EN-GB> <i>may affect up to 1 in 10&nbsp;people</i></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>F</span><span lang=EN-GB>ever, malaise, enlarged
liver, yellow colour of your skin and eyes, low blood cell counts due to severe
immune activation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dizziness or fainting, flushing, rash, itching,
fever, shortness of breath or vomiting, abdominal pain, diarrhoea due to
infusion related reaction</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash, nausea, vomiting, diarrhoea including
bloody stools (possible symptoms of graft-versus-host disease which is when
transplanted cells attack your cells)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black;background:white'>Pain in the
joints</span><span lang=EN-GB> due to high level of uric acid</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal blood test results (high level of:
phosphorus, potassium, calcium, magnesium and sodium, an enzyme called alkaline
phosphatase to help detect liver disease, fibrin d-dimer, serum ferritin; low
level of: blood protein called albumin, sodium)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Convulsion, fits (seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Involuntary or uncontrollable movements</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tingling or numbness, </span><span lang=EN-GB>difficulty
moving because of nerve damage</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Decreased vision</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Thirst</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>W</span><span lang=EN-GB>eight loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nerve pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Breathlessness, difficulty breathing when lying
down, swelling of the feet or legs (possible symptoms of h</span><span
lang=EN-GB>eart failure), stopped heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swelling and pain due to blood clots</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swelling due to fluids leaking from blood
vessels into the surrounding tissue</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bloating and discomfort (abdominal distension),due
to an accumulation of fluid in the abdomen</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dry mouth, sore mouth, bleeding in the mouth,
inflammation in the gums</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Yellow skin and eyes due to abnormally high
levels of bilirubin in the blood</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Itching</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Excessive sweating, n</span><span lang=EN-GB>ight
sweats</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bone and back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Flu&#8209;like illness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Failure of multiple organs</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon: </span></b><i><span lang=EN-GB>may affect up to 1 in
100&nbsp;people</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Weakness or paralysis of limbs or face,
difficulty speaking (possible symptoms of stroke as a result of reduced blood
supply)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Warm or rapidly reddening skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cough that produces phlegm or sometimes blood,
fever, shortness of breath or difficulty breathing</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you get any
side effects, talk to your doctor.</span><span lang=EN-GB style='color:red'> </span><span
lang=EN-GB>This includes any possible side effects not listed in this leaflet.</span><span
lang=EN-GB style='font-family:"Verdana",sans-serif'> </span><span lang=EN-GB>You
can also report side effects directly via <span style='color:black;background:
#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a></span><span lang=EN-GB>.</span><span
lang=EN-GB> By reporting side effects, you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.       How to store
Kymriah</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>The following information is intended for doctors only.</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the infusion bag label after EXP. The expiry date refers to the last day of
that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store and transport below &#8209;120°C. Do not thaw the product
until it is ready to be used.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use this
medicine if the infusion bag is damaged or leaking.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
contains genetically&#8209;modified blood cells. Local guidelines on handling
of biological waste should be followed for unused medicine or waste material.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.       Contents of the
pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Kymriah contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance of Kymriah is called tisagenlecleucel.
Each infusion bag of Kmyriah contains </span><span lang=EN-GB>tisagenlecleucel cell
dispersion at a batch&#8209;dependent concentration of </span><span lang=EN-GB>autologous
T cells genetically modified to express an </span><span lang=EN-GB>anti&#8209;CD19
chimeric antigen receptor</span><span lang=EN-GB> (CAR&#8209;positive viable T
cells). 1 or more bags contain a total of </span>1.2&nbsp;x&nbsp;10<sup>6</sup>&nbsp;–&nbsp;6&nbsp;x&nbsp;10<sup>8
</sup>CAR+ viable T cells.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The </span><span lang=EN-GB>other ingredients are
glucose, sodium chloride, human albumin solution, dextran 40 for injection,
dimethylsulfoxide, sodium gluconate, sodium acetate, potassium chloride,
magnesium chloride, sodium&#8209;N&#8209;acetyltryptophanate, sodium caprylate,
aluminium, and water for injections. See section&nbsp;2, “Kymriah contains
sodium, dimethylsulfoxide (DMSO) and dextran 40”.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Kymriah looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kymriah is a cell
dispersion for infusion. It is supplied as an infusion bag containing a cloudy
to clear, colourless to slightly yellow dispersion of cells. Each bag contains
10&nbsp;mL to 50&nbsp;mL of dispersion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black'>Novartis Europharm Limited</span></p>

<p class=MsoNormal style='margin-right:4.8pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='color:black'>Vista Building</span></p>

<p class=MsoNormal style='margin-right:4.8pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='color:black'>Elm Park, Merrion Road</span></p>

<p class=MsoNormal style='margin-right:4.8pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='color:black'>Dublin 4</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='color:black'>Novartis Pharma GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='color:black'>Roonstrasse 25</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='color:black'>90429 Nuremberg</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
style='color:black;background:#D9D9D9'>CELLFORCURE</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH style='color:black;background:#D9D9D9'>ZA de Courtabœuf</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR-CH style='color:black;background:#D9D9D9'>11 avenue des Tropiques</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='color:black;background:#D9D9D9'>91940 Les Ulis</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black;background:#D9D9D9'>France</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>For any information about this medicine, please contact
the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél/Tel: +32 2
  246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>SIA Novartis
  Baltics Lietuvos filialas</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: +370 5 269
  16 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis Bulgaria
  EOOD</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;</span><span
  lang=ES>: +359 2 489 98 28</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tél/Tel: +32 2
  246 16 11</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>&#268;eská
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +420 225
  775 111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Hungária Kft.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel.: +36 1
  457 65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Healthcare A/S</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: +45 39 16
  84 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +356 2122
  2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +49 911
  273 0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +31 </span><span
  lang=DE-CH style='color:black'>88 04 52 </span><span lang=DE-CH>555</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>SIA Novartis
  Baltics Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +372 66
  30 810</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Novartis
  Norge AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-BOK>Tlf: +47 23
  05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis (Hellas)
  A.E.B.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#932;&#951;&#955;:
  +30 210 281 17 12</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Pharma GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +43 1 86
  6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>España</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis
  Farmacéutica, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +34 93
  306 42 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Tel.: +48 22 375
  4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Pharma S.A.S.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Tél: +33 1 55
  47 66 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis Farma &#8209;
  Produtos Farmacêuticos, S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +351 21
  000 8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel. +385 1
  6274 220</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>România</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Pharma Services Romania SRL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +40 21 31299
  01</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Ireland Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +353 1
  260 12 55</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR-CH>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +386 1
  300 75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sími: +354 535
  7000</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Slovenská
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Novartis Slovakia
  s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +421 2
  5542 5439</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Novartis Farma
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +39 02 96
  54 1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Finland Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Puh/Tel: +358
  (0)10 6133 200</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR-CH>Novartis
  Pharma Services Inc.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#932;&#951;&#955;:
  +357 22 690 690</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE-CH>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Novartis
  Sverige AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>Tel: +46 8 732
  32 00</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>SIA Novartis
  Baltics</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +371 67 887
  070</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Novartis
  Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 1276
  698370</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><span class=MsoHyperlink>http://www.ema.europa.eu</span></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><b><span
lang=EN-GB style='color:black'>The following information is intended for
healthcare professionals only:</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:-1.85pt;margin-bottom:.0001pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Preparation of the infusion bag</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The timing of thaw of Kymriah and of infusion should be coordinated.
Confirm the infusion time in advance and adjust the start time for thaw so that
Kymriah is available for infusion when the recipient is ready. Once Kymriah has
been thawed and is at room temperature (20°C&#8209;25°C), it should be infused
within 30&nbsp;minutes to maintain maximum product viability, including any
interruption during the infusion.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The infusion bag should be placed inside a second, sterile bag
during thawing to protect ports from contamination and avoid spills in the
unlikely event of the bag leaking. Kymriah should be thawed at 37°C using
either a water bath or dry thaw method until there is no visible ice in the
infusion bag. The bag should be removed immediately from the thawing device and
kept at room temperature (20°C&#8209;25°C) until infusion. If more than one infusion
bag has been received for the treatment dose (refer to the batch certificate
for number of bags constituting one dose), the next bag should only be thawed
after the contents of the preceding bag have been infused.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Kymriah should not be manipulated. For example, Kymriah should not
be washed (spun down and resuspended in new media) prior to infusion.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The infusion bag(s) should be examined for any breaks or cracks
prior to thawing. If the infusion bag appears to have been damaged or to be
leaking, it should not be infused and should be disposed of according to local guidelines
on handling of biological waste.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Administration</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Kymriah intravenous infusion should be administered by a healthcare
professional experienced with immunosuppressed patients and prepared to manage
anaphylaxis. </span><span lang=EN-GB>Ensure that one dose of tocilizumab per
patient and emergency equipment are available prior to infusion and during the
recovery period. </span><span lang=EN-GB>Hospitals should have access to
additional doses of tocilizumab </span><span lang=EN-GB>within 8&nbsp;hours</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The patient’s identity should be matched with the patient
identifiers on the infusion bag. </span><span lang=EN-GB>Kymriah is for
autologous use only. Kymriah should be administered as an intravenous infusion
using latex&#8209;free intravenous tubing without a leukocyte depleting filter,
at approximately 10 to 20&nbsp;mL per minute by gravity flow. All contents of
the infusion bags should be infused. Sterile sodium chloride 9&nbsp;mg/mL
(0.9%) solution for injection should be used to prime the tubing prior to
infusion as well as rinse it afterwards. When the full volume of Kymriah has
been infused, the infusion bag should be rinsed with 10 to 30&nbsp;mL sodium
chloride 9&nbsp;mg/mL (0.9%) solution for injection by back priming to ensure
as many cells as possible are infused into the patient.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Precautions to be taken before handling or administering Kymriah</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Kymriah contains genetically&#8209;modified human blood cells. Local
guidelines on handling of biological waste should be followed for disposal.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>All material that has been in contact with Kymriah (solid and liquid
waste) should be handled and disposed of as potentially infectious waste in
accordance with local guidelines on handling of biological waste.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Kymriah should be transported within the facility in closed, break&#8209;proof,
leak&#8209;proof containers.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Kymriah is prepared from autologous blood of the patient collected
by leukapheresis. Patient leukapheresis material and Kymriah may carry a risk
of transmitting infectious viruses to healthcare professionals handling the
product. Accordingly, healthcare professionals should employ appropriate
precautions (wearing gloves and glasses) when handling leukapheresis material
or Kymriah to avoid potential transmission of infectious diseases.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
